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LIST OF ABBREVIATIONS AND DEFINITIONS

Atherosclerosis: a type of vascular disease characterized by plaque buildups in
arteries resulted from increased cytokines due to metabolic dysfunction, which leads
to activation of the innate immune system and chronic inflammation.
Beige adipocytes: a newly defined type of adipocytes within the white adipose
tissues. They are similar to brown adipocytes in that they express UCP1 and have
capacity for thermogenesis. They have a distinct gene expression signature from
either brown adipocyte or white adipocyte.
BAT: brown adipose tissue, which is a type of fat tissue that is abundant in rodents
and newborn human but less abundant in adult human, and with high capacity for
adaptive thermogenesis. Brown adipocytes contain numerous mitochondria
expressing UCP1, which uncouples proton gradient from ATP production, to
generate heat. Due to their ability to burn lipids (through β-oxidation) to generate
heat, brown adipocytes increase energy expenditure and are negatively associated
with obesity.
Browning: a phyisological transition of white adipose tissue, which shows
increased content of beige adipocyte.
DAPT: N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycine t-butyl ester, is a
γ-secretase inhibitor and widely used to inhibit Notch signaling in cell culture.
DBZ: dibenzazepine, is a γ-secretase inhibitor and widely used to inhibit Notch
signaling in aniaml study.
DLL1: Delta-like 1, a member of Delta/Serrate/Lag (DSL) family protein, which is

x
single-pass transmembrane protein whose extracellular domain acts as a ligand for
Notch receptors on a neighbor cell. In mammals, the other family members include
Delta-like (Dll3, Dll4) and Jagged (Jag1, Jag2).
Gluconeogenesis: a biochemical process that generates glucose from noncarbohydrate carbon substrates like pyruvate.
Glycogenolysis: a biochemical process whereby glycogen is broken down to
glucose-1-phosphate.
Glycolysis: a biochemical process that converts glucose to pyruvate, releasing free
energy in the form of ATP.
Hey: Hairy/enhancer-of-split related with YRPW motif protein, nuclear proteins
that belong to the hairy and enhancer of split-related (HESR) family of basic helixloop-helix (bHLH)-type transcriptional repressors. Hey expression is induced by
Notch signaling.
Hes: Hairy and enhancer of split, transcription repressors that belong to the bHLH
protein family with important roles in the Notch signaling pathway.
Lipodystrophy: a disease condition characterized by a partial or total loss of
adipose tissues, which can be divided into congenital and acquired subtypes.
M1 and M2 macrophage: also known as classically and alternatively activated
macrophages, respectively. M1 macrophages are activated in response to bacterial
infections or lipopolysaccharide and interferon-γ, and are highly inflammatory. In
contrast, M2 macrophages are activated in response to parasitic infections, or
interleukin 4 and -13, and are anti-inflammatory.
NICD: Notch intracellular domain, the transcriptional activation domain of Notch
receptor.
Notch receptors (Notch1-4): a family of single pass transmembrane receptors
consisted of an extracellular domain, a transmembrane domain and an intracellular
domain. Activation of Notch receptors leads to release of Notch intracellular domain,

xi
which then acts as a transcriptional factor to regulate gene expression.
Pparγ: peroxisome proliferator-activated receptor gamma, an important nuclear
receptor that controls gene transcription program of adipocytes.
PGC1α: Pparg cofactor 1a, a master regulator of beige adipocyte and mitochondria
biogenesis.
Prdm16: PR domain containing 16, a nuclear cofactor of Pparγ and is essential for
beige adipocyte specification.
Rbpj: recombination signal binding protein for immunoglobulin kappa j region,
also known as CBF1 in humans, is a highly conserved DNA-binding protein that
mediates canonical Notch signaling.
SVF: stromal vascular fraction, which is produced by enzymatic digestion of adipos
tissues and mainly contains adipocyte precursor cells, blood cells, macrophages et
al.
WAT: white adipose tissue, a major type of fat in animals and humans that store
energy in form of triglycerides.
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ABSTRACT

Bi, Pengpeng. Ph.D., Purdue University, May 2015. Notch Signaling Regulates
Adipogenesis and Energy Metabolism. Major Professor: Shihuan Kuang.

Evolutionarily unprepared for high caloric diets and sedentary lifestyles, humans
are now unprecedentedly susceptible to obesity and its associated metabolic
disorders. Obesity is resulted from malfunction of the overloaded white adipocytes,
which are the primary default storage sites of energy surplus. Another two types of
adipocytes can also be found in human: beige and brown adipocytes. In opposite to
white adipocytes, beige and brown adipocytes ameliorate obesity by burning lipids
for thermogenesis. Thus, an increase in beige/brown adipocyte content in adipose
tissue, termed browning would raise energy expenditure and reduce adiposity.

Notch signaling is a fundamental signal transduction pathway, which is critical for
development and metabolism. Here I report that adipose-specific Notch mutant mice
showed browning of white adipose tissue (WAT) and elevated expression of UCP1,
a key regulator of thermogenesis. Consequently, Notch mutants exhibit elevated
energy expenditure, improved glucose tolerance and insulin sensitivity, and are
more resistant to high fat diet (HFD)-induced obesity.

At the molecular level, constitutive activation of Notch signaling inhibits, whereas
Notch inhibition induces transcription of Ppargc1a and Prdm16, two master

xiii
regulators of beige adipocyte biogenesis. Notably, pharmacological inhibition of
Notch signaling in obese mice increases insulin sensitivity and ameliorates obesity,
accompanied by elevated UCP1 expression in white fat.

In contrast to Notch-inhibition, the mice with constitutive activation of Notch
signaling specifically in adipocytes, henceforth referred to as Adipoq/N1ICD
showed defect of beige adipocyte biogenesis, accompanied by severe glucose
intolerance and insulin resistance. Surprisingly, instead of developing obesity,
Adipoq/N1ICD mice showed scarcity of WAT, or lipodystrophy under both standard
diet and obesogenic HFD feeding regimes. This result indicates a potent inhibitory
effect of Notch signaling on white adipogenesis. Supporting this notion, expressions
of many white adipocyte marker genes were dramatically reduced in WAT of
Adipoq/N1ICD mice. Remarkably, chronic lipodystrophy in Adipoq/N1ICD mice
leads to development of fatty liver, hyperglycemia, hyperinsulinemia and cancers.

In summary, this study revealed two previously unknown functions of Notch
signaling in regulating adipocyte plasticity. While Notch inhibition promotes the
beige adipogenesis, chronic activation of Notch leads to paucity of both white and
beige adipocytes. Consequently, inhibition of Notch signaling improves, while
activation of Notch signaling deteriorates glucose metabolism. Therefore, Notch
signaling may be therapeutically targeted to treat obesity and its affiliated
comorbidities.

Keywords: Notch signaling, adipocytes, obesity, metabolic syndromes
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CHAPTER 1. INTRODUCTION

1.1. Introduction to Adipocytes
Adipocytes are known as fat cells, a type of cell that is specialized for energy storage.
Adipocytes are located in many different sites of the body, either exist abundantly
in adipose tissues or disperse scarcely within the other types of soft tissues,
including muscle, skin, perivascular and epicardial regions. In the energy surplus
state, adipocytes store energy in the lipid-droplets. In the negative energy state,
adipocytes undergo lipolysis process to break down lipids to fuel the other organs
(Sethi and Vidal-Puig, 2007). Besides serving as the energy buffer, adipose tissues
also insulate and protect the internal organs from physical damages. Importantly,
adipose tissues are also active endocrine organs, which synthesize and secrete
peptides, known as adipokines that regulate many aspects of systematic physiology
(Table 1.1) (Ouchi et al., 2011). Among them, Leptin and Adiponectin are two
adipokines that are abundantly expressed by mature adipocytes, which directly
regulates energy balance and insulin sensitivity, respectively (Coleman and
Hummel, 1973; Zhang et al., 1994). Malfunctions of Leptin and Adiponectin
pathways are directly linked to obesity and T2D (Lin et al., 2013).
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Table 1.1 List of adipokines

Adipokine

Adipocyte
specific

Major Function

Obese vs
Lean

Leptin

Yes

satiety

Increased

Adiponectin
Adipsin

Yes
Yes

Insulin sensitivity
β cell function

Decreased
Decreased

Resistin

No

Atherosclerosis

Increased

Visfatin

No

Arthritis

Increased

TNFα

No

Inflammation

Increased

IL-6

No

Inflammation

Increased

Reference
(La Cava and
Matarese, 2004)
(Lihn et al., 2005)
(Lo et al., 2014)
(Steppan et al.,
2001)
(Chang et al.,
2011)
(Hotamisligil et
al., 1995)
(Eder et al., 2009)

In mammals, three types of fat cells: white, brown and beige adipocytes can be
found in different anatomical positions. Brown adipocytes are found in brown
adipose tissues (BAT), which are mainly located in interscapular regions, whereas
beige and white adipocytes are intermingled together in white adipose tissues (WAT),
which spread in subcutaneous and abdominal regions. Of note, brown, beige and
white adipocytes have distinct development origins, cellular compositions and gene
expression signatures (Table 1.2) (Harms and Seale, 2013). Lineage tracing studies
showed that brown adipocytes are derived from Myf5+ lineage, while white and
beige adipocytes are mostly from Myf5– lineage (Seale et al., 2008). In addition,
despite all located in WAT, white and beige adipocytes are enriched in Pax3+ and
Pax3– lineage populations respectively (Liu et al., 2013). By storing energy, white
adipocytes are evolved to cope with food shortage and famine. By contrary, brown
and beige adipocytes are specialized to burn lipids stored by white adipocytes to
generate heat to defend against hypothermia.
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Table 1.2 Key features of brown, beige and white adipocytes

Cell

In adult
human

Origin
Myf5

Brown

+

Small
numbers
Myf5–

Beige
White

Abundant

Myf5–

Marker
Zic1
Lhx8
P2rx5
Cd137
Tbx1
Pat2
Asc-1
Tcf21

Cell
size

Lipid
content

Mitocho
ndria #

Small

multilocular

High

Middle

multilocular

Middle

Large

unilocular

Low

1.2. Adipocytes and Metabolic Syndromes
The emerging epidemics of obesity posed enormous challenges to human public
health. People are diagnosed as obesity with a body mass index (BMI) larger than
30 kg/m2. Obese patients have greatly increased risks of developing a broad range
of chronic diseases including type 2 diabetes (T2D), nonalcoholic fatty liver,
cardiovascular diseases and certain types of cancers. The fundamental feature of
obesity is the malfunction of white adipocytes, which undergo pathogenic
transitions. Although adipose tissues are the default and primary lipid storage sites,
adipocytes have limited expandability (Vidal-Puig, 2013). When the energy surplus
exceed the storing capacity of white adipose tissues, lipids will be spilled into
circulation and ectopically deposited in muscle and liver, deteriorating the glucoseprocessing functions of these organs, thus leading to high blood glucose levels
(hyperglycemia) and insulin resistance, two hallmarks of T2D. Therefore, the risk
of developing obesity-associated comorbidities depends on the expandability of
adipocytes, which is determined by genetic and nutritional factors (Slawik and
Vidal-Puig, 2007). Of note, proper interaction between macrophages and adipocytes
also regulates healthy expansion of adipose tissues (Surmi and Hasty, 2008). In
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obese adipose tissues, apoptotic adipocytes attract infiltration of proinflammatory
macrophages, which underline the systemic low-grade inflammation mechanism of
obesity (Martinez-Santibanez and Lumeng, 2014). Finally, the lipo-, glucotoxicities, together with the escalating inflammatory cytokines from adipose tissues
cause damages of many other organs, including the hardening of artery, known as
atherosclerosis (Grundy, 2002).

Despite many detrimental effects of obese-prone white adipocytes, proper
expansion of these cells in the other hand is also essential for health. Paradoxically,
in both animal models and humans, the deficiency of adipogenesis, termed as
lipodystrophy is associated with metabolic syndromes that are also observed in
obese subjects (Huang-Doran et al., 2010). Nevertheless, in both lipodystrophy and
obesity, the two extremities of adiposity, lipid redistribution into other non-adipose
organs is the initiating and determining factor of the systemic diseases (HuangDoran et al., 2010).

Contrary to white adipocytes, brown/beige adipocytes are specialized to burn lipids
that are stored by the white adipocytes. The thermogenesis of brown/beige
adipocytes depends on UCP1 (uncoupling protein 1), which uncouples the
mitochondria proton gradient to generate heat instead of ATP (Wu et al., 2013). The
high energy demands require high density of mitochondria and their oxidative
activity in brown/beige adipocytes. The active metabolism in turn boosts the uptake
of glucose and fatty acids from blood, therefore rendering brown/beige adipocytes
the anti-obesity and anti-diabetes properties (Wu et al., 2013). Such active catabolic
metabolism in brown/beige adipocytes are in striking contrast with low catabolicwhile high anabolic- metabolism of white adipocytes. Therefore, brown/beige
adipocytes are attractive therapeutic agents for reducing white adiposity, thus
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preventing or treating obesity, as well as its life-threatening comorbidities. As
expected, mice with overexpression of UCP1 showed a dramatic increase of energy
expenditure, which protected the mice from diet-induced obesity as well as diabetes
(Kopecky et al., 1995; Rossmeisl et al., 2002). Similar beneficial effects were also
recapitulated in transgenic mice that showed increased numbers of beige adipocytes
and upregulation of UCP1 expression in white adipose tissues (browning) (Harms
and Seale, 2013).
1.3. Molecular Regulation of Adipogenesis
Interestingly, adipose tissue expansion is not a passive process. Instead it’s tightly
orchestrated by a cascade of transcriptional events under influence of hormones and
nutrients (Rosen and MacDougald, 2006). The master regulators of adipogenesis are
Pparγ and C/EBP proteins (Tanaka et al., 1997). Pparγ is a member of nuclear
hormone receptor superfamily. Studies showed that Pparγ is both sufficient and
necessary for adipogenesis. As such, ectopic overexpression of Pparγ in fibroblast
and myoblast induced transdifferentiation of these cells into adipocytes (Hu et al.,
1995; Tontonoz et al., 1994). In the other hand, there is no genetic factor that can
stimulate adipogenesis in the absence of Pparγ (Rosen and MacDougald, 2006).
Despite such dramatic effect of Pparγ in adipogenesis, its endogenous ligand is still
unknown. However, studies found that several natural lipid species, including
eicosanoid and linoleic acids can bind with and stimulate the transcriptional activity
of Pparγ, though at a much lower affinity, compared with many other nuclear
hormone receptors as well as the synthetic ligands of Pparγ, thiazolidinediones
(TZDs). TZDs are highly effective insulin-sensitizing drugs that are prescribed to
treat T2D (Spiegelman, 1998). However meta-analysis of clinical trials of TZDmedication revealed several side-effects of long-term use, including the body weight
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gain, fluid retention, heart failure and bone loss (Loke et al., 2011; Mannucci et al.,
2008). Animal studies indicate that both the beneficial and detrimental effects of
TZDs are mediated through Pparγ. Interestingly, the broad effects of TZDs are
mediated by Pparγ not only in adipose tissues, but also through Pparγ activities in
many other organs (Tontonoz and Spiegelman, 2008). Insights into the tissuespecific actions of Pparγ would help to develop the demanding strategies to
eliminate the adverse effects of TZD drugs.

The upstream regulators of Pparγ are C/EBPβ and C/EBPδ (Wu et al., 1996). During
adipocyte differentiation, expression of C/EBPβ and C/EBPδ precede Pparγ
expression (Shao and Lazar, 1997). In cultured preadipocytes, ectopic expression of
C/EBPβ and C/EBPδ upregulates Pparγ, which indicates the direct regulation of
Pparγ by the C/EBP proteins (Christy et al., 1989). Indeed, the transcriptional
binding sites of C/EBP proteins are found in the promoter of Pparγ, which are
essential for the transcriptional induction of Pparγ (Salma et al., 2006). Interestingly,
another member of C/EBP family, C/EBPα is one of the downstream targets of Pparγ.
During the adipogenesis, expression of C/EBPα is followed by Pparγ. Ablation of
Pparγ both in vitro and in vivo resulted in the dramatic reduction of C/EBPα
expression, accompanied by the severe defect of adipocyte differentiation (Kubota
et al., 1999). Importantly, C/EBPα–/– embryonic fibroblast showed compromised
adipogenic potentials, as well as a reduction of Pparγ expression, which is
normalized when C/EBPα is introduced back to these cells (Wu et al., 1999). These
results point to a positive feedback loop between C/EBPα and Pparγ. Finally, both
C/EBPα and Pparγ can directly bind with and activate transcription of many
adipocyte-specific genes (Darlington et al., 1998; Gerhold et al., 2002; Nielsen et
al., 2008).
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Interestingly, the transcriptional factors introduced above are essential for
differentiation of all the three types of adipocytes, with C/EBPα as the only
exception (Rosen and MacDougald, 2006). Comparative gene expression analysis
of white and brown adipocytes leads to identification of two important cofactors of
Pparγ, Ppargc1α (Pparγ cofactor 1 α, Pgc1α) and Prdm16 (PR domain containing
16) that are essential for establishing and maintaining the key features of
brown/beige adipocytes (Handschin and Spiegelman, 2006; Seale et al., 2007).

Interestingly, mice with adipose-specific Pgc1α or Prdm16 knockout had normal
development of brown adipose tissues (Harms et al., 2014; Lin et al., 2004).
However the adaptive thermogenic functions of these brown/beige adipocytes are
dramatically impaired in these mutant mice (Harms et al., 2014; Uldry et al., 2006).
These results indicate that specification of brown/beige adipocytes is established
upon a general adipogenesis machinery that is shared by white adipocytes. Indeed,
functions of brown/beige adipocytes, but not white adipcoytes, are dynamical
regulated by a set of hormones, including FGF21, BMP7 and Irisin (Harms and
Seale, 2013). Irisin is a type of muscle hormone that is the cleaved and the biological
active form of Fndc5 (fibronectin type III domain containing 5) (Bostrom et al.,
2012). In the exercising myofibers, expression of Fndc5 is upregulated directly by
Pgc1α, a master regulator of mitochondrial biogenesis and oxidative metabolism in
muscle tissues (Bostrom et al., 2012). Circulating Irisin induces browning of WAT
through an unknown mechanism (Bostrom et al., 2012). Of note, a nearphysiological concentration of Irisin improved the glucose tolerance and protected
the mice from obesity (Bostrom et al., 2012). Consistently, in human, circulating
Irisin level was induced by cold stimulation, which upregulated UCP1 expression
and thermogenesis of cultured human adipocytes (Lee et al., 2014). Considering the
marked effects of Irisin on browning of human fat cells, it’s demanding to
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understand the regulation of Irisin secretion as well as to identify the receptor of
Irisin on adipocytes.
1.4. An Overview of Notch Signaling
The Notch signaling pathway is an evolutionarily conserved pathway important for
cell-cell communication and cell-fate determination during development, and is
required for adult tissue homeostasis. It consists of Notch receptors and Notch
ligands, as well as intracellular proteins that function to transmit the Notch signal to
the cell's nucleus. Notch receptors (Notch1-4) are single-pass transmembrane
proteins that are composed of an extracellular (NECD), a transmembrane (TM), and
an intracellular (NICD) domain. Notch ligands are also transmembrane proteins and
cells expressing Notch ligands must be in close proximity to Notch expressing cells
for signaling to occur. Ligands bind to the Notch NECD to induce proteolytic
cleavage and release of the NICD, which enters the cell nucleus to modify gene
expression. Notch ligands are members of the DSL (Delta/Serrate/LAG-2) family
proteins that include Delta-like (Dll1, Dll3, Dll4) and Jagged (Jag1, Jag2) in
mammals (Andersson et al., 2011; Kopan and Ilagan, 2009).

Notch signal transduction is initiated upon binding of a Notch receptor to a ligand
located on a neighbor cell (Figure 1.1). Endocytosis of Notch-bound ligand
generates a mechanical pulling force, which drives conformational changes of the
Notch receptor and facilitates its sequential proteolytic cleavages (Meloty-Kapella
et al., 2012). The first cleavage, mediated by a disintegrin and metalloproteinase
(ADAM) family peptidase, releases the NECD, whereas the second cleavage
mediated by γ-secretase releases the NICD (Kopan and Ilagan, 2009). NICD then
translocates to the nucleus where it binds with Rbpj (recombination signal binding
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protein for immunoglobulin kappa j region) and recruits a transcriptional complex
to activate the transcription of downstream targets, including Hes (Hairy/enhancerof-split) and Hey (Hes related with YRPW motif protein) family genes (Figure 1.1).
Simple in design, activation of Notch is tightly orchestrated at multiple levels
(Kopan and Ilagan, 2009) and the biological output is highly cellular-context
dependent. One unique and important feature of Notch signaling is the lack of
secondary amplification: NICD is part of Notch receptor as well as the direct
activator of Notch targets. Therefore, every single event of Notch activation engages
and consumes one Notch receptor. A similar turnover scenario applies to Notch
ligands as well. Notch ligand and receptor turnover together establish the oscillating
pattern of Notch activation based on the availability of replenished Notch receptors
and ligands. Nuclear NICD is eventually targeted for proteasomal degradation
mediated by the E3 ubiquitin ligase FBW7 (F-box and WD repeat domain
containing 7) (O'Neil et al., 2007; Perry and Li, 2008). A recent study has shown
that FBW7 transcription is repressed by the Notch target gene Hes5, thus creating a
positive feedback loop that prolongs Notch signaling (Figure 1.1) (Sancho et al.,
2013).

Notch signaling is a highly conserved intercellular communication mechanism
critical for many cellular processes including survival, proliferation and
differentiation, as well as maintaining stem cell quiescence and identity (Guruharsha
et al., 2012). As such, Notch signaling is widely employed to orchestrate proper
development, and perturbation of Notch pathway is linked to a variety of devastating
genetic disorders and cancers (Louvi and Artavanis-Tsakonas, 2012). In addition,
recent studies employing transgenic mouse models of tissue specific manipulation
of Notch signaling have begun to reveal the roles of Notch pathway in regulating
metabolism of several key metabolic organs.

10
1.5. Notch Signaling in Diabetic and Fatty Liver
Notch signaling is involved in embryonic development, postnatal regeneration and
carcinogenesis of the liver (Morell and Strazzabosco, 2014), the central hub for
glucose and lipid metabolism. Upon feeding, an increase in blood glucose stimulates
the secretion of insulin from the pancreas. Circulating insulin inhibits liver glucose
production, including glycogenolysis and gluconeogenesis, and stimulates glucose
utilization, including glycolysis and lipogenesis. Recent studies have revealed a key
role of Notch signaling in regulating both processes, with abnormal activation of
Notch signaling in hepatocytes leading to hyperglycemia and fatty liver disease
(Figure 1.2) (Pajvani et al., 2013; Pajvani et al., 2011).

The effect of Notch signaling on hepatic glucose production is mainly mediated
through synergy of NICD with the forkhead transcription factor FoxO1 (Figure 1.2).
FoxO1 directly activates the transcription of the catalytic subunit of glucose-6phosphatase (G6pc), a rate-limiting enzyme involved in hepatic glycogenolysis and
gluconeogenesis (Pajvani et al., 2011). Compound haploinsufficiency of FoxO1 and
Notch1 (Foxo1+/−:Notch1+/−) markedly ameliorates insulin resistance in dietinduced obese (DIO) mice (Pajvani et al., 2011). Liver-specific knockout of Rbpj
using Albumin-Cre phenocopies FoxO1:Notch1 haploinsufficiency, indicating that
Notch signaling is the key driver of hepatic insulin resistance. Consistently,
adenovirus-mediated activation of Notch1 in liver induces G6pc expression and
exacerbates insulin resistance in a FoxO1-dependent manner (Pajvani et al., 2011).
Importantly, pharmacological inhibition of Notch signaling by blocking γ-secretasemediated cleavage of NICD improves glucose tolerance and insulin sensitivity in
DIO mice (Pajvani et al., 2011).
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Another arm of insulin action in the liver is its stimulatory effect on lipogenesis. In
mouse and human diabetic mellitus, hepatic insulin resistance is selective, whereby
insulin fails to suppress gluconeogenesis but continues to stimulate lipogenesis,
resulting in hyperglycemia and hypertriglyceridemia. In contrast, mice with total
hepatic insulin resistance elicited by liver specific deletion of the insulin receptor
develop hyperglycemia but not hypertriglyceridemia (Biddinger et al., 2008; Brown
and Goldstein, 2008; Michael et al., 2000). These results suggest the existence of
divergent pathways controlling hepatic gluconeogenesis and lipogenesis.
Intriguingly, activation of hepatic Notch signaling leads to a selective insulin
resistance phenotype with hyperglycemia and hepatosteatosis (fatty liver) (Pajvani
et al., 2013). This result indicates that Notch signaling is a key point in the web of
the hepatic insulin paradox, where the two branches of insulin-action converge.
Mechanistically, Notch stimulates lipogenesis through an unknown factor that
stabilizes mTORC1 (mammalian target of rapamycin complex 1) (Pajvani et al.,
2013), a central player in lipid metabolism (Figure 1.2) (Lamming and Sabatini,
2013). Importantly, in both mouse and human, the hepatic Notch signaling is
positively correlated with insulin resistance and fatty liver disease (Pajvani et al.,
2013; Valenti et al., 2013).

One unanswered yet important question is about the upstream regulator of Notch
signaling in hepatocytes. A recent study indicates that the energy sensor AMPK
(AMP-activated protein kinase) regulates Notch signaling through mTORC1 under
influence of nutrient status (Li et al., 2014). Specifically, excessive amino acids
cause insulin resistance in cultured hepatocytes, accompanied by attenuation of
AMPK activity and activation of mTORC1-STAT3-Notch1 signaling (Figure 1.2)
(Li et al., 2014). The phenotypes are ameliorated by chronic administration of either
the AMPK activator metformin, or the mTORC1 inhibitor rapamycin (Li et al.,
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2014). Hence, the synergy between Notch and FoxO1, and the positive feedback
loop between Notch and mTORC1 in hepatocytes may be targeted to improve liver
insulin sensitivity and ameliorate hyperglycemia and hypertriglyceridemia caused
by diabetic fatty liver.

1.6. Notch Signaling Regulates Adipocyte Homeostasis
White adipose tissues (WAT) are the primary sites of long-term energy storage. In
response to excess caloric intake, the size of WAT expands through hyperplasia and
hypertrophy of adipocytes. Understanding the pathways that regulate adipocyte
homeostasis is thus fundamental to the treatment of obesity. Characterization of the
role of Notch signaling in adipocyte differentiation by various groups has generated
inconsistent results. In 3T3-L1 preadipocytes, the Notch target Hes1 is shown to
inhibit

adipogenic

differentiation

by repressing

expression

of

C/EBPα

(CCAAT/enhancer binding protein alpha) and Pparγ (peroxisome proliferatoractivated receptor gamma) (Ross et al., 2004). Paradoxically, knockdown of Hes1
also inhibits adipogenic differentiation of 3T3-L1 cells, accompanied by an
increased expression of Dlk1 (Delta-like 1 homolog), an inhibitor of adipogenic
differentiation (Ross et al., 2004). In human primary cell cultures, inhibition of
Notch promotes, whereas activation of Notch inhibits, adipogenic differentiation of
mesenchymal stem cells and adipose-derived precursor cells (Huang et al., 2010a;
Osathanon et al., 2012; Vujovic et al., 2007a). However, genetic ablation of several
key components of the Notch pathway fails to elicit any obvious deficiencies in
adipogenic differentiation of embryonic fibroblasts (Nichols et al., 2004). The
contradictory findings of these cell culture experiments could be attributed to the
timing and dosage effect of Notch intervention, and distinct cell types used. For
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instance, initiation of adipogenic differentiation of immortalized 3T3-L1 cells
requires sequential control of the cell cycle, which is directly affected by Notch
signaling (Lai et al., 2013; Noda et al., 2011). Another confounding factor is the
heterogeneity of primary preadipocyte cultures compared with 3T3-L1 cells (Berry
et al., 2013). It’s possible that adipocytes of different origins (or at different
differentiation stages) employ diverse combinations of Notch ligands and receptors
to achieve context-dependent versatility of Notch signaling. As these studies were
conducted in cultured cells, the function of Notch signaling in adipose tissues in
vivo remains unknown.
1.7. Notch Signaling in Skeletal Muscle Homeostasis
Skeletal muscle utilizes both glucose and free fatty acids as fuel for ATP production
during contraction. In addition, skeletal muscle is also a major site of glucose
storage, hence coordinately maintaining blood glucose level within the normal range.
In particular, the skeletal muscle accounts for 80-90% of postprandial insulinstimulated glucose uptake (Ferrannini et al., 1988; Thiebaud et al., 1982).
Importantly, skeletal muscle insulin resistance is identified as the primary defect in
T2D (DeFronzo and Tripathy, 2009). Furthermore, muscle exercise elicits strong
benefits against metabolic disorders. These benefits are not limited to the direct
energy expenditure during the muscle contraction, but also attributed to the muscle
secretome: cytokines and peptides produced by and released from skeletal muscle
cells (myofibers) to regulate body metabolism (Pedersen and Febbraio, 2012).
Therefore, maintaining muscle insulin sensitivity and its proper motor and secretory
functions are important prerequisites for treating metabolic diseases.
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Within the skeletal muscle, a pool of well-defined stem cells called satellite cells are
indispensable for the postnatal growth, maintenance and regeneration of myofibers
(Bentzinger et al., 2012). Notch signaling plays dose-dependent roles in satellite
cells (Mourikis and Tajbakhsh, 2014). High, intermediate and low/absent Notch
activities are essential for the quiescence (self-renewal), activation (cell cycle entry)
and differentiation of satellite cells, respectively (Bjornson et al., 2012; Conboy and
Rando, 2002; Mourikis et al., 2012; Wen et al., 2012). Specifically, deletion of either
Rbpj or Dll1 leads to premature differentiation and depletion of satellite cells,
resulting in a loss of postnatal muscle growth and severe muscle hypotrophy
(Bjornson et al., 2012; Mourikis and Tajbakhsh, 2014; Schuster-Gossler et al., 2007;
Vasyutina et al., 2007). Conversely, constitutive activation of Notch1 promotes the
self-renewal but inhibits differentiation of satellite cells, resulting in poor muscle
regeneration (Wen et al., 2012).

In addition to its well-established role in myogenesis, recent studies have pointed to
a potential role of Notch signaling in regulating muscle metabolism. In this regard,
the interaction between Notch and FoxO1 again appears to be essential. Muscle
specific knockout of FoxO1 promotes conversion of oxidative slow-twitch to
glycolytic fast-twitch myofibers in the soleus muscle (Kitamura et al., 2007). Using
the gold standard euglycemic hyperinsulinemic clamp technique, Pajvani et al found
that muscles of Foxo1+/−:Notch1+/− mice have considerably higher rates of glucose
uptake compared to those of wild type and Foxo1+/− mice (Pajvani et al., 2011),
though the fiber type composition in Foxo1+/−:Notch1+/− mice was not characterized
(Kitamura et al., 2007). This phenotype can be explained by either muscle specific
action of Notch1 and FoxO1, or secondary effect of Notch1:Foxo1
haploinsufficiency in non-muscle organs. It would be interesting to directly examine
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if myofiber-specific perturbations in Notch signaling affects muscle glucose
metabolism and insulin sensitivity in the future.
1.8. Notch in the Central Nervous System (CNS)
CNS plays a key role in orchestrating proper central neuroendocrine function, and
regulating systemic glucose and energy metabolism (Sandoval et al., 2009). Of note,
obesity is associated with structural and functional impairment of the CNS (Rusinek
and Convit, 2014), whose maintenance relies on neurogenesis mediated by adult
neural stem cells (NSCs) (Gage and Temple, 2013). Using tamoxifen-inducible
conditional Rbpj knockout mice, Imayoshi et al have recently found that deletion of
Rbpj in the adult brain caused transient differentiation of NSCs into neurons, leading
to a total loss of NSCs and blockage of subsequent neurogenesis (Imayoshi et al.,
2010). This indicates an indispensable role of Notch signaling in maintaining the
quiescence of NSCs in addition to its widely accepted role in inhibiting neuronal
differentiation. NSCs in the hypothalamus of DIO mice show impaired survival and
neurogenic functions (Li et al., 2012). Mechanistically, HFD feeding activates the
IKKβ/NF-κB-Notch signaling axis, which promotes apoptosis and impairs
neurogenic differentiation of NSCs (Li et al., 2012). Indeed, hypothalamus specific
activation of the pro-inflammatory IKKβ/NF-κB pathway phenocopies the effect of
HFD on NSCs, and ultimately leads to the development of obesity and diabetes (Li
et al., 2012). Intriguingly, the pro-inflammatory factor NF-κB directly binds to the
promoters, and activates expression of Dll4, Notch1 and Notch4 genes in NSCs (Li
et al., 2012). Consistently, inhibition of either IKKβ or Notch signaling reverses the
differentiation defect of hypothalamic NSCs of DIO mice (Li et al., 2012).
Collectively, NF-κB not only mediates systemic low-grade inflammation that is
critical for the initiation, development and exacerbation of metabolic syndrome
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(Baker et al., 2011), but also impairs neurogenesis through transcriptional
upregulation of Notch ligands and receptors during metabolic stress.

Notch signaling also functions as an important NSC niche factor in the CNS.
Endothelial cells of cerebral vessels enforce the quiescence of adult NSCs by
presenting Jag1 that activates Notch signaling in the neighboring NSCs (Ottone et
al., 2014). Endothelial cell lineage specific ablation of Jag1 results in aberrant
activation and depletion of quiescent NSCs (Ottone et al., 2014). In addition, both
HFD and high cholesterol diet increases expression of the Dll4 in the blood vessels
of an atherosclerotic mouse model (Fukuda et al., 2012). In summary, Notch
signaling must be temporally regulated in NSCs for proper neurogenesis. A low
Notch activity facilitates the differentiation of NSCs to immediately supply neurons
to repair nerve damage, and a high Notch activity facilitates quiescence and selfrenewal of NSCs. Dysregulation of Notch signaling in adult NSCs by obesity
associated systemic low-grade inflammation or pro-atherosclerotic vessels
represents a novel neurodegenerative mechanism in obese patients.
1.9. Notch in Metabolic Angiogenesis
It has been well-established that Notch signaling regulates the development of
embryonic vasculature, and perturbation of Notch pathway genes results in severe
vascular defects in mutant mice (Gridley, 2007). During development, Notch
signaling specifies arterial fate of endothelial cells (Roca and Adams, 2007). Notch
signaling also plays a critical role in controlling the differentiation of vascular
smooth muscle cells and senescence of endothelial cells in the postnatal vasculature
(Gridley, 2010). Moreover, the Notch pathway actively participates in vascular
remodeling by inhibiting the formation and function of endothelial tip cells via the
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regulation of VEGF signaling (Gridley, 2010). As vascular sprouting is
fundamentally important for the growth and expansion of white adipose tissue (Zhao
et al., 2013), understanding how Notch regulates angiogenesis has important
implications in obesity prevention and treatment. Compared to white adipose tissue,
brown adipose tissue is hypervasuclarized in order to meet the nutrients and oxygen
demands for its active thermogenic metabolism. Additionally, brown adipocytes
rely on the blood flow to diffuse the heat throughout the body to defend hypothermia.
Investigating whether and how Notch regulates angiogenesis in cold-activated
brown adipose tissue will extend the therapeutic scope of current preclinical trials
of Notch-inhibition based intervention of tumor angiogenesis (Zhao et al., 2013).

Of note, vascular dysfunction is not only involved in the development of obesity
(Zhao et al., 2013), but also a consequence of metabolic disorders manifested as
atherosclerosis and other types of cardiovascular diseases. Strikingly, blockade of
Dll4-Notch signaling using neutralizing anti-Dll4 antibody elicited a broad range of
benefits: dramatically attenuated the development of atherosclerosis, reduced
inflammation, improved insulin resistance, and ameliorated obesity (Fukuda et al.,
2012).

The vasculature also serves as the main niche factor for both brown and white
adipocyte precursors, therefore it may regulate adipose mass and body insulin
sensitivity (Zhao et al., 2013). Currently, it’s unclear how vasculature derived
adipose stem cells contribute to the heterogeneity of adipocytes, in terms of their
distinct differentiation potentials towards white versus beige/brown adipocytes.
Future work in characterizing how Notch signaling regulates the fate choice of
adipose stem cells in response to physiological (VEGF) and metabolic cues (insulin,
energy status) is warranted.
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1.10. Notch Regulates Metabolic Immunity
Notch signaling is emerging as an important regulator of both innate and adaptive
immune system development and function (Radtke et al., 2013), which have crucial
implications in metabolic syndrome (Sell et al., 2012). Among various cell types in
innate immunity, macrophages are the major players in terms of abundance and
functional significance in metabolic disorders. Macrophages can be divided into M1
and M2 macrophages. M1 macrophages are proinflammatory and secret
chemokines (e. g. monocyte chemotactic protein 1, MCP-1) and proinflammatory
cytokines (e. g. TNFα, tumor necrosis factor alpha) that directly increase
inflammation in peripheral tissues and impair local insulin sensitivity (Figure 1.3)
(Olefsky and Glass, 2010). On the other hand, M2 macrophages ameliorate obesityinduced inflammation and secrete anti-inflammatory cytokines (e. g. IL-10,
interleukin-10) that promote insulin sensitivity (Figure 1.3) (Olefsky and Glass,
2010). Importantly, Notch signaling regulates M1 versus M2 macrophages
specification, through different mechanisms (Figure 1.3) (Xu et al., 2012). First,
Rbpj promotes expression of the transcription factor IRF8 (interferon regulatory
factor 8) while suppresses expression of the histone H3 Lys 27 (H3K27)
demethylase JMJD3 (Jumonji domain containing 3) (Satoh et al., 2010), which are
inducers of M1 and M2 polarization respectively (Xu et al., 2012). Second, Notch
signaling boosts the inflammatory property of M1 macrophages by interacting with
NF-κB (Maniati et al., 2011; Monsalve et al., 2009). Compared to lean animals, DIO
mice showed a shift from a M2- to a M1-polarized state (Olefsky and Glass, 2010).
Consistently, Notch signaling in adipose tissue is activated by HFD feeding (Bi et
al., 2014), which in part can be explained by the infiltration of Notch-primed M1
macrophages. It is interesting to determine in the future whether and how inhibition
of Notch signaling promotes the transition from M1 to M2 macrophages in obese
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adipose tissues, and its therapeutic potentials against obesity and other metabolic
disorders.

Notch-mediated macrophage polarization contributes to the development of
metabolic disorders not only through the above-mentioned inflammatory actions,
but also through direct interaction with adipocytes. Notch ligands present on the cell
surface of macrophages can potentially activate Notch signaling in the neighboring
adipocytes, hepatocytes (Figure 1.2) and myofibers, and consequently exacerbate
the insulin resistance of these key peripheral tissues involved in energy metabolism.
Indeed, interferon (IFN)-γ, which activates M1 macrophages, induces Jag1
expression rapidly, therefore amplifying Notch signaling in neighbor cells (Foldi et
al., 2010).

Macrophage-adipocyte interaction is of significance in obesity and T2D mellitus,
where systemic infiltration of macrophages and other immune cells is prevalent. In
this scenario, dynamic Notch ligand presentation on these circulating cell types may
produce functional diversity in Notch activation, a direction deserving future
investigation. The complexity is encoded by the diverse signaling capacity of Notch
ligands and receptors (Ramasamy and Lenka, 2010), and preferential binding of
ligands to different Notch receptors (Andrawes et al., 2013). For instance, during
angiogenesis, Dll4 has strong, while Jag1 has weak signaling potential, and the
relative abundance of these ligands creates distinct outcomes in angiogenesis
(Benedito et al., 2009). Similarly, vasculature may also represent a crucial metabolic
niche factor by presenting Notch ligands to fine-tune Notch signaling in peripheral
tissues and metabolic disorders: either through regulating stem cells to maintain
homeostasis of neurons, myocytes and adipocytes or through directly regulating
enzyme expression in hepatocytes. These observations and speculations warrant
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future investigations into the metabolic phenotypes of mice with macrophage
specific deletion of Notch ligand genes. Answers to this question will shed light to
the distinct function of different Notch ligands in peripheral tissues, and potentially
enable tissue-specific Notch based therapy to treat metabolic disorders.
1.11. Summary of Notch Signaling in Regulating Metabolism
Notch signaling is a key regulator of cell fate and cellular homeostasis in virtually
every metabolic organ. In the liver, Notch signaling boosts the gluconeogenesis and
lipogenesis programs, which lead to hyperglycemia and fatty liver disease. In the
skeletal muscle and brain, Notch activation actively enforces the quiescence of local
adult stem cells, therefore limiting their tissue-repair potentials and subsequently
influencing body metabolism. In immune systems, activation of Notch signaling
promotes M1 macrophage polarization, producing a systemic low-grade
inflammation state that exacerbates insulin resistance in peripheral tissues.

Importantly, inhibition of Notch signaling in several of these tissues consistently
improves glucose tolerance, insulin sensitivity, and ameliorates obesity and
atherosclerosis. With the availability of pharmaceutical grade γ-secretase inhibitors
used in various clinical trials to treat Alzheimer’s disease and cancers (Andersson
and Lendahl, 2014), it would be feasible to examine the effect of these inhibitors in
treating diabetes and obesity in humans. Due to the gastrointestinal toxicity and
other off-target effects of γ-secretase inhibitors (Doody et al., 2013; Fleisher et al.,
2008; Siemers et al., 2006), however, alternative Notch inhibitors should also be
developed. In this regard, antibodies targeting Notch ligands and receptors have
recently been used in clinical trials (Andersson and Lendahl, 2014). The anti-obesity
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and anti-diabetic effect of these promising therapeutic agents should be investigated
in the future.
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Figure 1.1 Notch signaling transduction

A Notch receptor is synthesized as a precursor and cleaved by furin-like
convertase at site 1 (S1) in the Golgi compartment. Then it is targeted to the
cell surface as a heterodimer held together by noncovalent interactions. Upon
ligand and receptor binding, site 2 (S2) on Notch receptor is exposed and
cleaved by ADAM metalloprotease. S2 cleavage creates a membrane-tethered
intermediate, which is a substrate for the γ-secretase. γ-secretase complex
cleaves the Notch transmembrane domain progressively from site 3 (S3) to site
4 (S4) to release the Nβ peptide (not shown) and Notch intracellular domain
(NICD). NICD translates to the nucleus and binds to CSL and recruits a
transactivation complex including MAML1 to activate transcription of target
genes, including Hes and Hey family genes. Nuclear NICD is eventually
targeted for proteasomal degradation mediated by the E3 ubiquitin ligase
FBW7, which itself is negatively regulated by Notch target gene Hes5.
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Figure 1.2 Notch regulates gluconeogenesis and lipogenesis of hepatocytes

Notch signaling regulates hepatic glucose production through synergy with
FoxO1, which directly activates the transcription of G6pc and Pck1, the ratelimiting enzymes in hepatic glycogenolysis and gluconeogenesis, respectively.
Transcriptional-active FoxO1 is phosphorylated by AKT and excluded from
nucleus. In addition, Notch signaling promotes hepatic lipogenesis through an
unknown factor that stabilizes mTORC1, which is normally activated by
amino acids, as well as insulin-PI3K-AKT pathway. mTORC1 in turn
activates Srebp1c, a key factor that turns on transcription of Fasn, which
encodes a rate limiting enzyme in lipogenesis. In obesity, high levels of
glucose and free fatty acids (FFA) activate the AMPK-mTOC1-STAT3
pathway, which eventually upregulates Jag1 and activates Notch signaling in
the neighbor hepatocyte. Dotted line indicates indirect effect.
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Figure 1.3. Notch signaling and macrophage polarization

M1 (classically activated) and M2 (alternatively activated) macrophages are
activated by distinct and mutually exclusive activation programs. Notch
signaling promotes M1 macrophage polarization through synergy with NF-κB
and by upregulating expression of M1 macrophage regulator IRF8. Notch
signaling inhibits M2 macrophage polarization through repressing JMJD3, a
M2 macrophage regulator. M1 and M2 macrophages have distinct secretory
profiles, which oppositely control inflammation and impact systematic insulin
sensitivity. Abbreviation: IFNγ, Interferon gamma; LPS, Lipopolysaccharide;
IRF8, Interferon regulatory factor 8; JMJD3, Jumonji Domain Containing 3;
MCP-1, monocyte chemotactic protein 1.
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CHAPTER 2. NOTCH SIGNALING REGULATES ADIPOSE BROWNING
AND ENERGY METABOLISM

2.1. Abstract
Beige adipocytes in white adipose tissues (WAT) are similar to classical brown
adipocytes in that they can burn lipid storage to produce heat. Thus, an increase in
beige adipocyte content in WAT, (browning) would raise energy expenditure and
reduce adiposity. Here I report that adipose-specific inactivation of Notch1 or its
signaling mediator Rbpj in mice results in browning of WAT and elevated expression
of UCP1, a key regulator of thermogenesis. Consequently, Notch mutants exhibit
elevated energy expenditure, better glucose tolerance, improved insulin sensitivity,
and are more resistant to high fat diet (HFD)-induced obesity. By contrast, activation
of Notch1 signaling in adipocytes leads to opposite phenotypes. At the molecular
level, constitutive activation of Notch signaling inhibits, whereas Notch inhibition
induces, Ppargc1a and Prdm16 transcription in white adipocytes. Notably,
pharmacological inhibition of Notch signaling in obese mice ameliorates obesity,
reduces blood glucose and increases UCP1 expression in white fat. Therefore, Notch
signaling may be therapeutically targeted to treat obesity and Type 2 diabetes (T2D).
2.2. Introduction
Global epidemics of obesity and its associated risks of chronic diseases including
T2D pose formidable challenges to human health. Classical brown adipose tissues
(BAT) prominently found in rodents and hibernating mammals dissipate extra
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energy to generate heat through uncoupled respiration mediated by UCP1, and thus
increase energy expenditure and counteract obesity (Nedergaard and Cannon, 2010;
Rosen and Spiegelman, 2006; Smith, 1964; Tran and Kahn, 2010). Metabolically
active UCP1+ brown adipocytes have recently been detected in adult humans with
advanced imaging techniques (Cypess et al., 2009; Saito et al., 2009; van Marken
Lichtenbelt et al., 2009; Virtanen et al., 2009; Zingaretti et al., 2009). Interestingly,
human adipose depots are highly heterogeneous and the brown adipocytes coexist
with white and beige (brite) adipocytes (Cypess et al., 2013; Jespersen et al., 2013;
Lidell et al., 2013). Beige adipocytes are a class of adaptive thermogenic cells
located within various depots of WAT (Fisher et al., 2012; Frontini et al., 2013; Ohno
et al., 2012; Schulz et al., 2013; Seale et al., 2011). Recent studies indicate that beige
adipocyte homeostasis can be maintained through two mechanisms. First, they can
be generated de novo from a population of beige preadipocytes (Wang et al., 2013;
Wu et al., 2012). Second, they can be bidirectionally converted from and to white
adipocytes under the control of environmental temperature or sympathetic nerve
innervation (Cao et al., 2011; Rosenwald et al., 2013; Ye et al., 2013). Importantly,
elevated UCP1 expression in cold acclimated beige adipocytes is associated with
robust uncoupled respiration and thermogenesis (Shabalina et al., 2013). Notably,
appearance of beige or brown adipocytes in human is inversely correlated with
obesity and T2D mellitus (Ouellet et al., 2011; Pfannenberg et al., 2010), indicating
their important role in regulating metabolism. Thus, identifying mechanisms
underlying beige adipocyte biogenesis is instrumental to the development of
therapeutics to reduce adiposity and risks of obesity-related metabolic syndrome
that affect > 10% of the world population.

Notch signaling is activated by binding of Dll or Jag family ligands with Notch
receptors (Notch1–4), leading to γ-secretase mediated proteolytic cleavage and
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release of Notch intracellular domain (NICD) (Schroeter et al., 1998). NICD then
translocates to the nucleus where it binds with the Rbpj transcriptional complex to
activate the transcription of downstream targets, including Hes and Hey family
genes. Notch signaling has been shown to paradoxically either inhibit or facilitate
the adipogenic differentiation of 3T3 L1 cells (Garces et al., 1997; Lai et al., 2013;
Ross et al., 2004; Urs et al., 2012). In murine and human primary cell cultures,
Notch inhibition promotes, while Notch activation inhibits, adipogenic
differentiation of mesenchymal and adipose-derived stem cells (Huang et al., 2010b;
Osathanon et al., 2012; Vujovic et al., 2007b). However, genetic ablation of several
key components of the signaling pathway indicates that Notch signaling is
dispensable for adipogenesis of mouse embryonic stem cells or embryonic
fibroblasts derived from early embryos (Nichols et al., 2004). As these studies are
conducted in cultured cells, the function of Notch signaling in adipose tissues in
vivo remains unknown.
2.3. Specific Aims and Rationale
My long term goal is to understand the molecular control of adipocyte homeostasis,
which affect glucose, lipid and energy metabolism. To dissect role of Notch
signaling in adipocyte in vivo, I generated the adipose-specific Notch1 and its
signaling mediator, Rbpj knockout mouse models. I hypothesize that Notch
signaling defect in adipose tissues influences the identify of white versus beige
adipocyte, which finally leads to alteration of glucose and adiposity profile of the
Notch mutant mice. In parallel, I treated wild-type adipocyte culture with classic
Notch signaling inhibitor to validate the findings gained from Notch mutant mice.
For a molecular mechanism, I focused expression changes of several key regulator
genes of adipocyte function, including Pparγ, Pgc1a and Prdm16. As such,
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adipocyte samples with genetic and chemical inhibition of Notch signaling was
tested for gene expression changes. Finally, I evaluated therapeutic potentials of
Notch signaling inhibitors on glucose and energy metabolism of obese mice.
2.4. Materials and Methods
2.4.1. Animals
All procedures involving mice were performed in accordance with Purdue
University’s Animal Care and Use Committee. The Rbpjflox/flox mouse was previously
described (Han et al., 2002) and kindly provided by Tasuku Honjo (Kyoto
University). Other mice used were purchased from Jackson lab: Notch1flox/flox
(Stock# 007181) (Yang et al., 2004), aP2-Cre (Stock# 005069) (He et al., 2003),
Adiponectin–Cre (Stock# 010803) (Eguchi et al., 2011), Lepob (Stock# 000632)
(Coleman and Hummel, 1973). RosaN1ICD (Stock# 008159) (Murtaugh et al., 2003),
RosaEYFP (Stock# 007920). Mice were in C57BL/6J or mixed background and
housed in the animal facility with free access to water and standard rodent chow
food or high fat diet (TD.06414 Harlan). Energy intake assay was calculated by
measuring food consumption and data was presented as the food weight multiple its
energy content, then normalized to body weight of mice and # of days.
2.4.2. Indirect Calorimetry Study
Oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory
exchange ratio (VCO2/VO2) and heat production were measured using an indirect
calorimetry system (Oxymax, Columbus Instruments) installed under a constant
environmental temperature (22 °C) and 12:12 light cycle. Food and water were free
access to mouse in each chamber.
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2.4.3. Rectal Temperature Measurement
A digital thermometer (ETI model: MicroTherma 2) was used in combination with
a copper thermocouple probe (Type T). The probe was inserted 2 centimeters and
1.6 centimeters into anal duct of male and female adult mice (2–4 month-old),
respectively. Temperature was measured at around 4 pm.
2.4.4. Glucose Uptake in WAT Explants
Mice were fasted for 20 hours (from 6 pm to 2 pm of next day). Intact inguinal
adipose tissue was carefully dissected free of visible connective tissue, and placed
immediately in ice-cold PBS for 5 minutes. WAT explants were then transferred to
37 °C prewarmed DMEM (glucose free), supplemented with 10 nM insulin for 30
minutes at 37 °C with 5% CO2. For glucose consumption measurement, WAT was
then transferred to 24 wells with 1 ml DMEM supplemented with 100 nM insulin
and 1,000 mg L-1 glucose per well, and incubated at 37 °C with 5% CO2. Media (50
μl) were collected for glucose measurement at 60 and 120 minutes. Glucose
consumption was calculated based on the glucose concentration of media collected
and measured with glucose test strip (Accu-Check Active, Roche) read by a
glucometer (Accu-Check Active, Roche).The readings were calibrated based on a
standard curve plotted using a gradient of known concentrations of glucose in
DMEM (R2 > 0.99).
2.4.5. DBZ Treatment
DBZ was purchased from TOCRIS Bioscience (Cat. No. 4489) and used following
previous studies (Milano et al., 2004; Pajvani et al., 2011). DBZ was dissolved in
DMSO at 100 mM concentration. Upon use the stock was suspended at 1:100
dilution in a solution containing 0.5% Methocel E4M (w/v, Dow Chemical) and 0.1%
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TI en-80 (w/v Sigma) in H2O. This working solution was mixed by vortex and
sonication for 1 minute each, and IP injected at a dosage of 10 µmol DBZ per kg
body weight. Control groups were injected with equal volumes of DMSO diluted in
E4M/TI en-80 solution. Control and DBZ treatment groups were randomly grouped.
To test the effect of DBZ on genetic induced obesity, ob/ob (Lepob) mice (6-weekold, male) were treated every other day for one month.
2.4.6. Glucose Measurement
Five µl blood collected from tail vein was dropped onto glucose test strip (AccuCheck Active, Roche) and measured by a glucometer (Accu-Check Active, Roche).
For glucose tolerance tests, mice were given intraperitoneal (IP) injection of 100 mg
ml-1 D-glucose (2 g kg-1 body weight for standard diet fed, 1 g kg-1 for high fat diet
fed and 0.5 g kg-1 for Lepob mice) after overnight fasting, and tail blood glucose
concentrations were monitored. For insulin tolerance test, mice were fasted for 4
hours before IP administration of human insulin (Santa Cruz) (0.75 U kg-1 body
weight) and tail blood glucose concentrations were monitored. For both GTT and
ITT, mouse was singly caged with blinded cage number and random orders.
2.4.7. FACS and Immunostaining
SVF cells were isolated from inguinal WAT of 2-month old wild-type mice that
under chow diet. To examine subpopulations of macrophage cells in the SVF, cells
were sorted based on CD11b and F4/80 staining of SVF cells. For immunostaining,
the digested SVF cells were cultured overnight and attached cells were stained for
CD68 (ab955).

31
2.4.8. Primary Adipocyte Culture, Transfection and Chemical Treatment
Stromal-vascular fraction (SVF) cells were isolated from subcutaneous white
adipose tissue unless otherwise stated. Adipose tissue was minced and digested with
1.5 mg mL-1 collagenase at 37 °C for 1.5 ~ 2 hours. The digestions were stopped
with DMEM containing 10% FBS, filtered through 100 µm filters and centrifuged
at 450 × g for 5 minutes. SVF cells were seeded and cultured in growth medium
containing DMEM, 20% FBS, 1% penicillin/streptomycin at 37 °C with 5 % CO2
for 3 days. Upon confluence, the cells were collected and electroporated using a
Neon transfection system (Invitrogen). Briefly, 105 cells were suspended in 10 µl
electroporation buffer, including 2.5 μg plasmids and electroporated (1,100 V, 10
ms, 3 times) using a 10 μl tip. After electroporation, the cells were seeded and
cultured in 6–will plates. All plasmids used were cloned as described (Wen et al.,
2012). Preadipocytes were induced to differentiate with induction medium contains
DMEM, 10% FBS, 2.85 µM insulin, 0.3 µM dexamethasone (DEXA) (Sigma) and
0.63 mM 3-isobutyl-methylxanthine (IBMX) (Cayman Chemical) for 4 days, then
4 days in differentiation medium contains DMEM, 200 nM insulin and 10 nM T3
until adipocytes mature. During the induction and differentiation, cell was treated
with 10 μM DAPT (N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenylglycine tbutyl ester) (Cayman Chemical).
2.4.9. Adipocyte Oxygen Consumption rate (OCR) Measurement in vitro
Primary SVF cells from inguinal WAT were isolated and cultured for 3 days before
plated in XF cell culture microplates (Seahorse Bioscience). SVF cells (10,000 cells)
were seeded in each will and each sample has 8 replicates. After 6 days of
differentiation, cultured adipocytes were washed twice and pre-incubated in XF
medium for 1–2 h at room temperature. The oxygen consumption rate was measured
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by the XF extracellular flux analyzer (Seahorse Biosciences). The chemicals (final
concentration, 0.2 mM Palmitate: 34 μM BSA, 2 μM Rotenone) were preloaded into
cartridges and injected into XF wells in succession. OCR was calculated as a
function of time (picomoles per minute).
2.4.10. Total RNA Extraction, cDNA Synthesis and Real-time PCR
Total RNA was extracted from cells or tissues using Trizol Reagent according to the
manufacturer’s instructions. RNA was treated with RNase-free DNase l to remove
contaminating genomic DNA. The purity and concentration of total RNA were
determined by a spectrophotometer (Nanodrop 2000c, Thermo Fisher) at 260 nm
and 280 nm. Ratios of absorption (260/280 nm) of all samples were between 1.8
and 2.0. Then 5 μg of total RNA were reverse transcribed using random primers
with M-MLV reverse transcriptase (Invitrogen). Real-time PCR was carried out in
a Roche Light Cycler 480 PCR System with SYBR Green Master Mix (Roche) and
gene-specific primers listed in Table 2.1. The 2-∆∆Ct method was used to analyze the
relative changes in each gene’s expression normalized against 18S rRNA expression.
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Table 2.1 List of qPCR primers
Gene
18s-F
18s-R
Notch1-F
Notch1-R
Notch2-F
Notch2-R
Notch3-F
Notch3-R
Notch4-F
Notch4-R
Hes1-F
Hes1-R
Hey1-F
Hey1-F
Heyl-F
Heyl-R
Ucp1-F
Ucp1-R
Pgc1a-F
Pgc1a-R
Prdm16-F
Prdm16-R
Cidea-F
Cidea-R
Cd137-F
Cd137-R
Tbx1-F
Tbx1-R
Cpt1a-F
Cpt1a-R
Cpt2-F
Cpt2-R
Cox7a1-F
Cox7a1-R
Cox8b-F
Cox8b-R
Atgl-F

Sequence 5'-3'
AGT CCC TGC CCT TTG TAC ACA
CGA TCC GAG GGC CTC ACT A
TGG CCT GCC TGT CTG GAA CAA CAG TTC A
ACC CTT GCC TCA GTT CAA ACA CAA GAT AC
GAC TGC CAA TAC TCC ACC TCT
CCA TTT TCG CAG GGA TGA GAT
TGC CAG AGT TCA GTG GTG G
CAC AGG CAA ATC GGC CAT C
CTC TTG CCA CTC AAT TTC CCT
TTG CAG AGT TGG GTA TCC CTG
CCA GCC AGT GTC AAC ACG A
AAT GCC GGG AGC TAT CTT TCT
TGA ATC CAG ATG ACC AGC TAC TGT
TAC TTT CAG ACT CCG ATC GCT TAC
TCC TAG CCA GAG ATT CAG TGT CAC
GTT TGT CTG CAA CAC CCT AGA GTG
ACT GCC ACA CCT CCA GTC ATT
CTT TGC CTC ACT CAG GAT TGG
GGA TTG AAG TGG TGT AGC GAC
GCT CAT TGT TGT ACT GGT TGG A
CAG CAC GGT GAA GCC ATT C
GCG TGC ATC CGC TTG TG
TGC TCT TCT GTA TCG CCC AGT
GCC GTG TTA AGG AAT CTG CTG
CGT GCA GAA CTC CTG TGA TAA C
GTC CAC CTA TGC TGG AGA AGG
GGC AGG CAG ACG AAT GTT C
TTG TCA TCT ACG GGC ACA AAG
CTC AGT GGG AGC GAC TCT TCA
GGC CTC TGT GGT ACA CGA CAA
CAG TGC ACA GAA GCC TCT CTT G
CTT CCC AAT GCC GTT CTC AA
ACA ATG ACC TCC CAG TAC ACT
CCA AGC AGT ATA AGC AGT AGG C
AAG CCA GCC AAA ACT CCC ACT
TTT TTA TAG CTC TCC AAG TGG G
CTC ATT CGC TGG CTG CGG CT
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Table 2.1 Continued
Atgl-R
Hsl-F
Hsl-R
Leptin-F
Leptin-R
Cd68-F
Cd68-R
Il6-F
Il6-R
Il1b-F
Il1b-R

CCT GCC GAG GCC CCG TAG AT
GCT TGG GGA GCT CCA GTC GGA
CTC CTG GGC CCT GGC TTG AGA
GAG ACC CCT GTG TCG GTT C
CTG CGT GTG TGA AAT GTC ATT G
TGT CTG ATC TTG CTA GGA CCG
GAG AGT AAC GGC CTT TTT GTG A
GTT CTC TGG GAA ATC GTG GA
GGA AAT TCG GGG TAG GAA GGA
GCA ACT GTT CCT GAA CTC AAC T
ATC TTT TGG GGT CCG TCA ACT

2.4.11. Protein Extraction and Western Blot Analysis
Protein was isolated from cells or tissue using RIPA buffer contains 50 mM TrisHCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS.
Protein concentrations were determined using Pierce BCA Protein Assay Reagent
(Pierce Biotechnology). Proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a polyvinylidene
fluoride (PVDF) membrane (Millipore Corporation), blocking in 5% fat-free milk
for 1 hour at room temperature, then incubated with primary antibodies in 5% milk
overnight at 4 °C. The UCP1 (ab23841), N1ICD (ab8925) and Hes1 (ab71559)
antibodies were from Abcam, and PGC1-α (sc-13067), GAPDH (sc-32233) and
Actin (sc-130656) were from Santa Cruz Biotechnology. The horseradish
peroxidase (HRP) conjugated secondary antibody (anti-rabbit IgG or anti-mouse
IgG, Santa Cruz Biotechnology) was diluted at 1:5,000. Immunodetection was
performed using enhanced chemiluminescence Western blotting substrate (Pierce
Biotechnology) and detected with a Gel Logic 2200 imaging system (Carestream).
Alternatively, membrane was incubated with infrared secondary antibody (Alexa
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Fluor 790 goat anti-mouse IgG, A11357, Alexa Fluor 680 goat anti-rabbit IgG,
A21109, life technologies, USA) and the signals were detected by using the Odyssey
infrared image scanning system. Results shown in figures are representative result
from at least three independent experiments.
2.4.12. Hematoxylin-Eosin (H&E) and Immunohistochemistry (IHC) Staining
Adipose tissues were fixed in 10% formalin for 24 hours at room temperature. Then
the tissues were embedded into paraffin and cut at 4 µm thick, de-paraffinized, and
rehydrated through xylene, ethanol, and water by standard methods. For antigen
retrieval, slides were submerged in 0.01 M sodium citrate (pH 6.0) and heated to
96 °C for 20 minutes in a laboratory microwave (PELCO). Immunohistochemistry
was performed on a Dako Autostainer (Dako, Carpinteria, CA). Slides were
incubated with 3% hydrogen peroxide and 2.5% normal horse serum (S-2012,
Vector), followed by incubation with rabbit polyclonal anti-UCP1 primary antibody
diluted 1:200 in 2.5% normal horse serum (Vector, S-2012) for 60 minutes. Signal
was detected with an anti-rabbit IgG Polymer Detection Kit (MP-7401, Vector)
Labeling and was visualized with 3, 3’-diaminobenzidine (DAB) as the chromogen
(SK-4105, Vector). Slides were counterstained with Harris hematoxylin (EK
Industries, Joliet, IL) and whole slide digital images were collected at 20X
magnification with an Aperio Scan Scope slide scanner (Aperio, Vista, CA). Images
shown were representative result of at least three biological replicates. Scanned
images of H&E staining were analyzed by Photoshop CS3 to calculate cell numbers.
Averaged adipocyte size was calculated as the image area divided by cell numbers.
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2.4.13. Chromatin Immunoprecipitation (ChIP) and Genomic DNA
Recombination Assay
Cultured inguinal adipocyte of both wild-type and mutant mice was cross-linked
with 1% formaldehyde in DMEM medium for 10 minutes at room temperature
followed by the addition of 125 mM glycine for 5 min at room temperature, after
which cells were washed 1 time with ice-cold PBS and scraped into SDS lysis buffer.
The cells were further sonicated and diluted for immunoprecipitation with the
indicated antibodies. The immunoprecipitates were eluted and reverse cross-linked
overnight at 65 °C. DNA fragments were purified using the Cycle Pure kit (Omega
Bio-Tek), and qPCR was performed with primers listed in Table 2.2. Genomic DNA
was extracted from adipose tissue and amplified with primers listed in Table 2.2.
Table 2.2 Primer sequences for DNA recombination and ChIP-qPCR assay
Site
PTC
Notch1 KO
Rbpj KO
Primer1
Primer2
Primer3
Primer4

Sequence 5'-3'
5'-TAAGCCTGCCCAGAAGACTC-3'
5'-AAAGTCGCTCTGAGTTGTTAT-3'
5'-TGGCCTGCCTGTCTGGAACAACAGTTCAGG-3'
5’-ACCCTTGCCTCAGTTCAAACACAAGATACG-3’
5'-CTTGATAATTCTGTAAAGAGA-3'
5'-CCACAGGCAACAATTGAG-3'
5'-GCCGTGTTAGCAGGGATTTA-3'
5'-AGGTCCTCTTGGGGAACAGT-3'
5'-TGAGGTGAAGACCGAGAAGG-3'
5'-CGCACAGAGCACTCAATCTG-3'
5'-CACAAAAGCTGTCGTCTGGA-3'
5'-GCACCTTCTGCACCTTTTTC-3'
5'-TTTCAGTGTTTTTCCTTCATT-3'
5'-CCCAGAAAACAAATGCTAGA-3'
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2.4.14. Luciferase Assay
HEK293A cells were seeded into 12–will plate 1 day before lipofectamine 2000
mediated transfection. PGC1-α promoter luciferase plasmid was purchased from
Addgene, generated by Handschin C, et al (Handschin et al., 2003). For transfection
of each well, 100 ng Renilla plasmid, 400 ng pGL3-Basic (or pGL3-PGC1-α) and
600 ng Hes1 plasmid (or its blank control plasmid) were cotransfected following
manufacture’s instruction. Cells were harvested 36 hours after transfection and
analyzed with Dual-Luciferase Reporter Assay System (Promega).
2.4.15. Statistical Analyses
Trial experiments or experiments done previously were used to determine sample
size with adequate statistical poI r. Measurement values that are beyond fence as
determined by interquartile range were considered as outlier and excluded from
following statistical analysis. All analyses were conducted with student t test with
two-tail distribution. Comparison with a P value < 0.05 was considered significant.
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2.5. Results
2.5.1. White to Brown Fat Transition in Adipose-Specific Notch Mutant Mice
I first examined the relative expression of Notch pathway genes in different depots
of WAT. Notably, the mRNA levels of Notch receptors and Notch targets were much
higher in the visceral epididymal (Epi) WAT than the subcutaneous inguinal (Ing)
WAT (Figure 2.1A,B). By contrast, BAT-specific Ucp1, Ppargc1a and Prdm16
were expressed at lower levels in the EpiWAT than IngWAT (Figure 2.1C). An
inverse correlation between activated Notch1 (N1ICD) and UCP1 at the protein
level was also observed (Figure 2.1D). These results suggest that Notch signaling
may play a role in regulating BAT-specific gene expression in vivo.

To directly investigate how Notch signaling regulates adipose plasticity in vivo, I
established an adipose tissue-specific Notch1 knock-out (KO) mouse model: aP2Cre/Notch1flox/flox, henceforth named as aNotch1. To validate the tissue specificity
of aP2-Cre, I evaluated YFP fluorescence in different organs of aP2-Cre/RosaEYFP
reporter mice. As expected, adipocytes were all YFP+, but liver and muscle tissues,
two important regulators of lipid and glucose homeostasis other than adipose tissue,
were predominately YFP– with only few YFP+ interstitial cells (Figure 2.2A).
Adipose macrophages, accounting for < 2% of total stromal vascular fraction (SVF)
cells, were also predominantly YFP– (Figure 2.2B,C).

PCR-based genotyping confirmed DNA recombination in mutants’ adipose tissues
(Figure 2.3A). Accordingly, Notch1 expression was ~ 65% lower in adipose tissues
and 85% lower in mature adipocytes, but unchanged in other tissues of the aNotch1
mice when compared to the wild-type (WT) mice (Figure 2.3B). Notably, various
depots of subcutaneous WAT of aNotch1 mice appeared browner than their WT
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counterparts (Figure 2.3C). In addition, the weight of various fat depots was lighter
in the aNotch1 compared to WT mice (Figure 2.3D). Furthermore, multilocular
UCP1+ beige adipocytes were much more abundant in the IngWAT of aNotch1
versus in WT mice (Figure 2.4A). The average adipocyte sizes of aNotch1 WAT
were ~ 40% smaller than those of WT (Figure 2.4B).

At molecular level, expression of Ucp1, Cidea, Prdm16, Ppargc1a genes were
upregulated in the IngWAT of aNotch1 mice compared with WT mice (Figure 2.5A).
Western blot confirmed the higher UCP1 protein levels in the aNotch1 IngWAT
(Figure 2.5B). In addition, mRNA levels of beige cell markers (Cd137, Tbx1),
mitochondria genes (Cpt1a, Cpt2), and lipolysis enzymes (Atgl, Hsl) were all
considerably higher in aNotch1 versus WT IngWAT (Figure 2.5C–E).

To examine the effect of Notch1 in visceral WAT and BAT, I checked the adipocyte
sizes and gene expression in these depots. Similar as observed in IngWAT, the
visceral EpiWAT of aNotch1 mice also contains smaller lipid-droplet containing
adipocytes (Figure 2.6A), thus smaller averaged adipocyte sizes (Figure 2.6B). At
molecular level, EpiWAT of aNotch1 mice express higher browning-related genes
(Figure 2.6C,D). Surprisingly, I didn’t find any significant changes in BAT of the
aNotch1 mutant mice (Figure 2.6 E).

In parallel I generated another mouse model, aP2-Cre/Rbpjflox/flox (aRbpj).
Genotyping and quantitative PCR (qPCR) confirmed the deletion of Rbpj DNA
(Figure 2.7). Again, browner appearance of IngWAT was observed in aRbpj when
compared with WT mice (Figure 2.7B), associated with higher levels of BATspecific genes (Figure 2.7C,D). However, expression of these genes were not
altered in the BAT (Figure 2.7E).
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Recent lineage tracing studies showed that the aP2-Cre expression can be detected
in several non-adipose organs, including brain and liver (Lee et al., 2013; Martens
et al., 2010; Mullican et al., 2013a; Urs et al., 2006). Therefore, the browning
phenotype of aNotch1 and aRbpj mice could be a secondary effect of Notch1
deletion in these organs. To rule out this possibility, I generated another highly
adipocyte-specific Notch1 knockout mice, in which deletion of Notch1 was
mediated by Adiponectin (Adipoq)-Cre, henceforth known as Adipoq/Notch1 mice.
Consistent with the observation of aNotch1 and aRbpj mice, Adipoq/Notch1 mice
showed dramatic increase of UCP1 expression in white adipose tissues, compared
with littermate wild-type mice (Figure 2.8).
2.5.2. Improved Glucose Metabolism in Notch Mutant Mice
In rodents and humans, brown adipocytes are shown to improve glucose metabolism
and insulin sensitivity (Orava et al., 2011; Stanford et al., 2013). To check whether
browning of WAT in aNotch1 mice elicits beneficial metabolic effects, I conducted
intraperitoneal (IP) glucose- and insulin-tolerance tests (GTT and ITT, respectively).
Compared to their WT siblings, the aNotch1 mice had extraordinary glucose
clearance ability, manifested by lower blood glucose concentrations after glucose
injection (Figure 2.9A). Likewise, the aNotch1 mutant mice exhibited faster and
persistent glucose clearance after insulin injection (Figure 2.9B). I further measured
insulin-stimulated glucose uptake by IngWAT explants dissected from aNotch1 and
WT mice, and found that aNotch1 IngWAT absorbed ~ 65% more glucose than their
WT counterparts (Figure 2.9C). Improved glucose tolerance and insulin-stimulated
glucose clearance were also observed in the aRbpj mice (Figure 2.10). These in vivo
and ex vivo experiments together suggest that the genetic disruption of Notch
signaling in adipose tissue improves insulin sensitivity and blood glucose tolerance.
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A physiological characteristic of beige cells is their highly active metabolism
coupled to thermogenesis. I examined the metabolic rate of aNotch1 mice using
indirect calorimetry approach. The aNotch1 mice had higher rates of oxygen (O2)
consumption and carbon dioxide (CO2) production, and expended more energy than
WT mice (Figure 2.11).
To examine whether the metabolic changes are dependent on UCP1 function, mice
were acclimated at thermoneutral condition (28.3 ºC) for 3–5 weeks to block
functional activation of UCP1. Notably, thermoneutrality abolished the beneficial
metabolic phenotypes of the aNotch1 mice observed at room temperature, but not
UCP1 protein expression (Figure 2.12 and 2.13). This result suggests that browning
of WAT in the aNotch1 mice leads to UCP1-dependent improvements of energy
expenditure.

Contrary to thermoneutrality, cold stress induces formation of beige adipocytes and
their adaptive thermogenesis through UCP1 upregulation and sympathetic nerve
stimulation (Cannon and Nedergaard, 2011). Notably, IngWAT of aNotch1 mice
contained many more clusters of UCP1+ cells than the WT counterparts after
exposed to 4 ºC for 1 week (Figure 2.14A). In addition, adipocytes in the aNotch1
IngWAT are predominantly multilocular and UCP1+, whereas WT IngWAT only
contain a small fraction of such cells (Figure 2.14B). These morphological changes
were associated with elevated expression of UCP1 and PGC1-α in cold-acclimated
aNotch1 compared to WT IngWAT (Figure 2.14B). These results indicate that
aNotch1 mice are more adaptive to cold-induced thermogenesis.
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2.5.3. The aNotch1 Mice Were Resistant to HFD-induced Obesity
In light of their better glucose tolerance, insulin sensitivity and higher metabolic
rate, I predicted that the aNotch1 mice should be resistant to HFD-induced obesity.
Indeed, the aNotch1 mutant mice were leaner after fed with HFD for 4 weeks
(Figure 2.15A), even though their daily energy intake was similar to that of the WT
littermates (Figure 2.15B). In addition, the aNotch1 mice retained better glucose
tolerance and higher insulin sensitivity after HFD feeding (Figure 2.16).

This observation prompted us to examine if HFD activates Notch signaling in WT
mice. Upon HFD treatment, expression of Lep, a surrogate indicator of mature
adipocytes and obesity, was increased by 20 folds (Figure 2.17A), confirming the
obesogenic effect of HFD. Coincidentally, mRNA and protein expression of Notch
receptors and targets were induced by HFD (Figure 2.17). These results together
suggest that activation of Notch signaling is associated with, and inactivation of
Notch conversely prevents, HFD-induced obesity.
2.5.4. Adipocyte-specific Activation of Notch Signaling Inhibits Browning and
Glucose Metabolism
As a complementary approach to the knockout mouse models, I carried out gain-offunction studies using Adiponectin (Adipoq)-Cre/RosaN1ICD mice (henceforth
Adipoq/N1ICD). As expected, adipose tissue of Adipoq/N1ICD mice had higher
expression levels of N1ICD, Hes1 and Hey1 (Figure 2.18). The Adipoq/N1ICD
mice were slightly (~ 6%) heavier than their WT littermates even though they had
similar food intake (Figure 2.19). Notably, the Adipoq/N1ICD mice had lower
glucose tolerance and insulin sensitivity compared with WT littermates (Figure
2.20). At molecular level, Adipoq/N1ICD mice had lower expression levels of
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thermogenic and mitochondrial respiration-related genes in the IngWAT, but not in
BAT (Figure 2.21).
Despite the normal levels of browning-related gene expression in BAT, the
Adipoq/N1ICD BAT is whiter and larger (Figure 2.22), and H&E staining revealed
adipocytes with larger numbers and sizes of lipid droplets, compared their WT
counterparts (Figure 2.22). Compared to the WT mice, the Adipoq/N1ICD mice
also displayed blunted cold-induced browning, manifested by lower abundance of
UCP1+ beige adipocytes and lower expression levels of UCP1 and PGC1-α proteins
in IngWAT after acclimated to 4 ºC (Figure 2.23). Thus, genetic activation of Notch
signaling in adipocytes impairs body energy metabolism.
2.5.5. Notch Signaling Inhibits the Expression of Prdm16 and Ppargc1a in White
Adipocytes
To understand the cellular and molecular mechanisms through which Notch
signaling regulates adipocytes, I first employed loss-of-function studies in cell
culture. I cultured SVF preadipocytes from subcutaneous WAT of the Notch1flox/flox
mice. Upon transfection with a plasmid encoding Cre, the expression of Notch1 and
its downstream target Hes1 were reduced by more than 50% (Figure 2.24A). This
is accompanied by an upregulation Prdm16 and Ppargc1α expression (Figure
2.24B). In parallel, I inhibited Notch signaling in WT white adipocytes with a γsecretase inhibitor, DAPT (Figure 2.25A). This treatment upregulated the
expression of Ucp1, Cidea, Prdm16, and Ppargc1a genes (Figure 2.25B,C).
Moreover, aNotch1 inguinal adipocytes exhibited higher O2 consumption rate (OCR)
than WT adipocytes upon stimulation with palmitate (Figure 2.25D). These results
demonstrate that inhibition of Notch signaling cell-autonomously enhances the

expression of brown (beige) adipocyte-specific genes and cellular respiration of
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white adipocytes.

I also performed Notch gain-of-function studies using SVF cells isolated from the
subcutaneous WAT of RosaN1ICD mouse, which overexpresses (OE) the constitutive
active N1ICD upon Cre induction (Figure 2.26A). Accordingly, Prdm16 and
Ppargc1a were inhibited by the N1ICDOE (Figure 2.26B). As N1ICDOE upregulates
Hes1 and Hey1, I next investigated if OE of these genes are sufficient to mimic the
observed effect of N1ICDOE. Indeed, either Hes1OE or Hey1OE repressed the
expression of Prdm16 and Ppargc1a (Figure 2.27A–C).

These results prompted us to ask whether the transcriptional repressor Hes1 can
directly bind with the promoter of Prdm16 and Ppargc1a. Bioinformatics analysis
identified consensus N-Box (CACNAG) sites in the proximal promoter regions of
mouse and human Prdm16 and Ppargc1a genes (Figure 2.28A). Chromatin
immunoprecipitation (ChIP) using a Hes1 antibody followed by qPCR assay using
primers flanking the N-Box region showed that these predicted binding sites in
Prdm16 and Ppargc1a promoter regions were enriched by 3- and 13-fold,
respectively (Figure 2.28B). However, enrichment of these regions was abolished
in aNotch1 adipocytes (Figure 2.28B). As a control, the Hes1 antibody failed to
enrich random promoter regions that do not contain the N-Box sequence (Figure
2.28B), confirming the specificity of Hes1 binding to N-Box. Furthermore, Hes1
inhibited PGC1-α promoter-driven luciferase reporter activity (Figure 2.28C).
These results suggest that the canonical Notch target Hes1 can directly bind to the
promoters of Prdm16 and Ppargc1a to repress their expression, therefore inhibiting
brown (beige) gene programs.
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2.5.6. Notch Inhibition Induces Browning and Ameliorates Obesity in Lepob Mice
To explore the therapeutic potential of targeting Notch signaling to improve glucose
metabolism, I treated WT mice with a pharmacological inhibitor of the Notch
signaling. I injected littermate mice of similar body weight with dibenzazepine
(DBZ), a γ-secretase inhibitor, or vehicle control for 5 days consecutively. Notably,
DBZ treated mice had better glucose tolerance and insulin sensitivity than the
vehicle control treated mice (Figure 2.29A,B). At the molecular level, DBZ
treatment resulted in higher Ucp1 mRNA and protein expression in IngWAT and
EpiWAT (Figure 2.29C,D). Adipocyte volume and number are positively correlated
with leptin production(Rosenbaum and Leibel, 1999), and I found that Lep
expression and adiposity were reduced, but UCP1+ adipocytes were increased after
DBZ treatment (Figure 2.29E,F). Hence, Notch inhibition reduced adiposity and
improved glucose homeostasis in healthy mice.

To further investigate if Notch inhibition ameliorates obesity under pathological
conditions, I treated ob/ob mice deficient of Lep (Lepob) with DBZ. Mice were
randomly grouped and showed no difference in body weight gain prior to treatment
(Figure 2.30A). Notably, DBZ treatment nearly blocked the body weight gain seen
in the vehicle-treated control group, without affecting energy intake (Figure 2.30).
The body weight differences were due to reduced size and weight of various WAT
depots in the DBZ-treated mice (Figure 2.30C,D). DBZ treatment also reduced liver
weight and hepatic lipid accumulation (Figure 2.30 and Figure 2.31), consistent
with previous observation that Notch promotes lipogenesis in hepatocytes and liver
steatosis(Pajvani et al., 2013). In addition, glucose tolerance and insulin sensitivity
were improved by DBZ treatment (Figure 2.32).
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At the molecular level, DBZ inhibited the expression of Notch targets Hes1, Hey1
and Heyl as well as Lep (Figure 2.33A), but upregulated Ucp1 and Ppargc1a
expression (Figure 2.33B,C). DBZ also suppressed expression of inflammatory
cytokines Cd68, Il6 and Il1b (Figure 2.33D) that are associated with obesity in
humans (Weisberg et al., 2003). At end of the experiment, fed blood glucose
concentrations remained low, regardless of DBZ injection (Figure 2.33E),
suggesting a long-term beneficial effect of adipose browning on glucose metabolism.
These results all together provide strong evidence that Notch signaling pathway can
be pharmacologically targeted to prevent and treat obesity, and to improve glucose
tolerance and insulin sensitivity.
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Figure 2.1 Notch signaling is inversely correlated with expression of brown
fat-related gene

(A-C) Notch receptor (A), target (B), and brown fat-related gene (C)
expression in epididymal white adipose tissue (Epi-WAT) and inguinal white
adipose tissue (Ing-WAT), n = 5. (D) Representative Western blots showing
N1ICD and UCP1 expression in Epi-WAT and Ing-WAT. *P < 0.05, **P <
0.01, ***P < 0.001. Data are means ± SEM.
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Figure 2.2 aP2-Cre lineage tracing assay

(A) YFP fluorescence in white adipose tissue, liver and muscle of aP2Cre/RosaEYFP mice, arrow points YFP+ cells. (B) CD68 (red color)
immunostaining to show macrophage (arrow) in cultured inguinal SVF cells
from 2-month-old aP2-Cre/RosaEYFP mice. (C) Fluorescence-activated cell
sorting of CD11b+ and F4/80+ macrophages from inguinal SVF cells of 2month-old mice under standard chow diet (left), and ratio of macrophage in
SVF cells (n = 3, right).
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Figure 2.3 Browning phenotype of WAT in Notch mutant mice

(A) Gel electrophoresis result of PCR using primers to detect Notch1
deletion in aNotch1 mice, lane 1, 3, 5 are WT tissues, lane 2, 4, 6 are mutant
tissues, lane 7 is PCR without template, PTC, positive control of genomic
DNA. (B) Expression of Notch1 in various tissues or cells. (C)
Representative images of anterior-subcutaneous WAT (arrows) and IngWAT
(asterisks), lower panel shows IngWAT. (D) Ratio of adipose tissue weight
to body weight, n = 7 except for epiWAT (n = 9). *P < 0.05, **P < 0.01,
***P < 0.001. Data are means ± SEM.
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Figure 2.4 Histology study of adipose tissues of aNotch1 mice

(A) Representative images of Hematoxylin & Eosin (H&E) and UCP1
staining of IngWAT (left), scale bar, 50 μm. (B) Average inguinal
adipocyte size. *P < 0.05, **P < 0.01, ***P < 0.001. Data are means ±
SEM. n = 4 pairs of mice unless otherwise indicated.
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Figure 2.5 Increased thermogenic genes in aNotch1 mutant mice

(A) mRNA levels of genes in WT and aNotch1 WAT. (B) Western blot result.
(C-E) mRNA level of genes in adipose tissues. *P < 0.05, **P < 0.01, ***P <
0.001. Data are means ± SEM. n = 4 pairs of mice.
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Figure 2.6 Characterization of epididymal WAT of aNotch1 mutant mice

(A) Representative H&E staining images of epididymal WAT. Scale bar
represents 50 um. (B) Average adipocyte size quantified from A. (C,D)
Gene expression in epididymal WAT, n = 6. (E) Gene expression in brown
adipose tissue (BAT) of aNotch1 (n = 7). *P < 0.05, **P < 0.01. Data are
means ± SEM.
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Figure 2.7 Browning of WAT of aRbpj mutant mice

(A) Gel electrophoresis result of PCR using primers to detect Rbpj deletion in
aRbpj mice, lane 1, 3, 5 are WT tissues, lane 2, 4, 6 are mutant tissues, lane 7
is PCR without template, PTC, positive control of genomic DNA. (B)
Representative images of IngWAT from WT and aRbpj mice. (C,D) Gene
expression in IngWAT. (E) Gene expression in brown adipose tissue (BAT) of
aRbpj mice. *P < 0.05, **P < 0.01, ***P < 0.001. Data are means ± SEM. n =
4 pairs of mice.
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Figure 2.8 UCP1 expression in WAT of Adipoq/Notch1 mice

(A) Western blot result. (B) Band intensity analysis, arbitrary unit. **P <
0.01. Data are means ± SEM. n = 3 pairs of mice.
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Figure 2.9 Improved glucose metabolism in aNotch mutant mice

(A,B) Blood glucose concentrations during IP-GTT (A) and IP-ITT (B)
performed on 2–4 month-old WT and aNotch1 mice, n = 6. (C) Insulin
stimulated glucose uptake of IngWAT explant from fasted 2–4 month-old WT
(n = 4) and aNotch1 mice (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Data
are means ± SEM.
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Figure 2.10 Improved glucose metabolism in aRbpj mutant mice

(A,B) Blood glucose concentrations during IP-GTT (A, n = 4) and IPITT (B, n = 10) performed on 2–4 month-old WT and aRbpj mice. *P
< 0.05, **P < 0.01, ***P < 0.001. Data are means ± SEM.
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Figure 2.11 Increased metabolic rates of aNotch mutant mice

(A–C) Average day and nigaht O2 consumption, CO2 production, and heat
production, n = 6. *P < 0.05, **P < 0.01, ***P < 0.001. Data are means ±
SEM.
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Figure 2.12 Characterization of aNotch1 mice acclimated at thermoneutral
condition (28.3 °C)

(A,B) Blood glucose levels during IP-GTT (A, n = 4) or IP-ITT (B, n = 3).
(C) Western blot result of UCP1, Notch1 and Hes1 in inguinal WAT. *P <
0.05, **P < 0.01. Data are means ± SEM.
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Figure 2.13 Metabolic rates of aNotch1 mice acclimated at thermoneutral
condition (28.3 °C)

(A-D) Averaged day and night O2 consumption, CO2 production, respiration
exchange ratio (RER) and heat production, n = 5. *P < 0.05, **P < 0.01.
Data are means ± SEM.
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Figure 2.14 Cold-stimulated browning of aNotch1 mice

(A) Representative histological analysis result of IngWAT from aNotch1
and WT mice treated at 4 °C for 1 week, scale bar, 1 mm (middle), 50 μm
(right). (B) Western blot of white adipose tissues from WT and aNotch1
mice after cold stimulation.
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Figure 2.15 aNotch1 mice were resistant to HFD-induced obesity

(A,B) Growth curve (A, n = 5) and energy intake assay (B, n = 4) of WT
and aNotch1 mice fed with HFD. *P < 0.05, **P < 0.01, ***P < 0.001.
Data are means ± SEM.
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Figure 2.16 Glucose and insulin tolerance test of aNotch1 mice

(A) Blood glucose concentrations during IP-GTT after glucose injection into
fasted mice. (B) Blood glucose concentrations during IP-ITT after injecting
insulin into fasted mice.. *P < 0.05, **P < 0.01, ***P < 0.001. Data are
means ± SEM.
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Figure 2.17 Notch signaling was activated by HFD feeding

(A) Gene expression assay of Notch receptors, Notch targets and Lep in WAT
from 3 weeks’ standard diet (SD) and HFD fed mice, n = 8. (B) Representative
result of western blot for Notch activity of sample as in A.*P < 0.05, **P <
0.01, ***P < 0.001. Data are means ± SEM.
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Figure 2.18 Relative expression of N1ICD and its target genes in WAT
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Figure 2.19 Body weight and food intake measurement
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Figure 2.20 Glucose profile of Adipoq/N1ICD mice

(A,B) Blood glucose concentrations during IP-GTT (A, n = 6) and IP-ITT
(B) performed on 5–8 week-old WT and Adipoq/N1ICD mice. *P < 0.05,
**P < 0.01, ***P < 0.001. Data are means ± SEM.
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Figure 2.21 Reduced beige adipocyte marker gene expression in WAT of
Adipoq/N1ICD mice

(A,B) Relative expression of BAT and mitochondria marker genes in IngWAT
(A) and BAT (B). (C) Western blot of IngWAT. N = 4 . *P < 0.05, **P < 0.01,
***P < 0.001. Data are means ± SEM.
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Figure 2.22 Histology study of BAT of Adipoq/N1ICD mice

(A) Representative image of BAT. (B) H&E staining of BAT section, scale
bar, 50 μm. (C) Representative H&E and UCP1 staining images of IngWAT
from mice acclimated at 4 °C for 2 weeks, scale bar = 100 μm. (D) Western
blot of IngWAT sample as in panel C.
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Figure 2.23 Histology study of adipose tissues of Adipoq/N1ICD mice

(A) Representative H&E and UCP1 staining images of IngWAT from mice
acclimated at 4 °C for 2 weeks, scale bar = 100 μm. (B) Western blot of
IngWAT sample as in panel C.
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Figure 2.24 Deletion of Notch1 induces expression of Ppargc1a and
Prdm16 genes in cultured white adipocyte

(A,B) Gene expression of Notch1 and Hes1 (A), Prdm16 and Ppargc1a
(B). N = 3 . *P < 0.05 and **P < 0.01. Data are means ± SEM.
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Figure 2.25 Inhibition of Notch signaling induces expression of Ppargc1a and
Prdm16 genes in cultured white adipocyte

(A,B) Gene expression of Notch target genes (A), beige adipocyte genes (B),
n = 3 . (C) Protein level of N1ICD, UCP1, PGC1-α . (D) OCR of cultured
wild-type and aNotch1 inguinal adipocytes. *P < 0.05 and **P < 0.01. Data
are means ± SEM.

72

Figure 2.26 N1ICD inhibits expression of BAT marker genes

(A,B) Gene expression in RosaN1ICD preadipocytes after transfection with
Cre or GFP (control) plasmids. N = 3. *P < 0.05 and **P < 0.01. Data are
means ± SEM.
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Figure 2.27 Notch target genes inhibit BAT marker gene expression

(A-C) Gene expression of WT preadipocytes after transfection with Hey1
(A,B) or Hes1 (C) plasmids. n = 3. *P < 0.05 and **P < 0.01. Data are means
± SEM.
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Figure 2.28 Hes1 directly binds to the promoters of Pgc1α and Prdm16

(A) Conserved N box domains on Prdm16 (top) and Ppargc1a (bottom)
promoters of both human and mouse. (B) Chromatin immunoprecipitation
(ChIP) using Hes1 antibody folloI d by qPCR assay, n = 4. (C) Luciferase assay
of HEK293 cells after cotransfection of pGL3-PGC1-α (or pGL3-Basic)
plasmids with Renilla plasmids and Hes1 (or its control, ctrl) plasmids, n = 5.
*P < 0.05 and **P < 0.01. Data are means ± SEM. n = 3 unless otherwise
indicated.

75

Figure 2.29 Notch inhibitor DBZ induces browning and ameliorates glucose
metabolism

(A,B) Blood glucose level during GTT (A) or ITT (B), n = 4. (C) Relative
expression of Ucp1 in IngWAT and VisWAT after treatment with DMSO or
DBZ, n = 5. (D) Representative Western blot result. (E) Relative expression
of Leptin in WAT, n = 6. (F) H&E and UCP1 staining of IngWAT from mice
after 5 days DMSO or DBZ treatment, scale bar = 50 μm. *P < 0.05, **P <
0.01. Data are means ± SEM.
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Figure 2.30 DBZ ameliorates obesity of Lepob mice

(A) Body weight ratio normalized to day 0, arrows mark doses of DMSO or
DBZ injection. (B) Energy intake assay. (C) WAT images. (D) Tissue weight.
*P < 0.05, **P < 0.01, ***P < 0.001. Data are means ± SEM.
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Figure 2.31 DBZ reduces adipocyte size and improves fatty liver of
Lepob mice

(A,B) H&E staining result of IngWAT (A), and adipocyte size (B). (C)
H&E staining of liver, scale bar represents 100 μm. **P < 0.01. Data are
means ± SEM.
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Figure 2.32 DBZ improves glucose tolerance and insulin sensitivity of Lepob
mice

(A,B) Plasma glucose measurement during IP-GTT (A), or during IP-ITT
(B), n = 5. *P < 0.05, **P < 0.0. Data are means ± SEM.
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Figure 2.33 DBZ induces browning of Lepob mice

(A-D), Relative expression of Notch targets (A), adipocyte genes (B), UCP1
protein (C), and inflammation-related genes (D) in IngWAT. (E) Fed-plasma
glucose concentrations at dates shown, arrows indicate DMSO or DBZ
injection. *P < 0.05, **P < 0.01, ***P < 0.001. Data are means ± SEM, n = 5.
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2.6. Discussion
Our study reveals a previously unrecognized yet critical role of Notch signaling in
regulating the browning of adipose tissues and body insulin sensitivity. I have
provided compelling genetic, physiological, metabolic, histological, cellular and
molecular evidence to demonstrate that blockage of Notch signaling promotes
browning of WAT. Conversely, activation of Notch signaling represses expression
of genes critical for BAT biogenesis in vitro as well as in vivo, and is associated with
whitening of WAT and HFD-induced obesity. As Notch signaling is highly
conserved in the animal kingdom, I anticipate that our results in mice will be
applicable to humans, though future studies dissecting the role of Notch signaling
in human adipose tissues are imperative.

I used the aP2-Cre mice to drive deletion of Notch1 or Rbpj in adipose tissues.
Although the aP2-Cre expression domain falls predominantly in immature and
mature adipocytes, leaky expression of this promoter was reported in several other
cell types (Lee et al., 2013; Martens et al., 2010; Mullican et al., 2013a; Urs et al.,
2006). Coincidently, Notch inhibition has been shown to improve insulin sensitivity
through regulating liver lipid metabolism and attenuating atherosclerosis (Fukuda
et al., 2012; Pajvani et al., 2011). Even though I used the more adipocyte-restricted
Adipoq-Cre mouse (Eguchi et al., 2011) to show that Notch activation conversely
induces whitening of BAT and reduces glucose tolerance, I cannot exclude the
possibility that Notch signaling in other cell types may have also contributed the
metabolic improvements of the aNotch1 mice.

White to brown fat transition involves a series of cellular processes, including
increased Ucp1 expression and mitochondria production, lipolysis, and β-oxidation.
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These features are all observed in the WAT but not BAT of Notch mutant mice. The
differential responses of BAT and WAT to Notch signaling are perhaps due to the
different embryonic origin of these tissues as well as cell type specific gene
regulatory programs.

I used ChIP assay to demonstrate that the transcriptional co-repressor Hes1 directly
binds to the promoter regions of Ppargc1a and Prdm16, whose expression are
inhibited by Hes1 overexpression. Hey proteins can inhibit expression of Hes1
targets through dimerization with Hes1 (Iso et al., 2001). Consistent with this notion,
I observed that overexpression of Hey1 also inhibits the transcription of Ppargc1a
and Prdm16. In addition, NICD may recruit GCN5, a cofactor of Rbpj transcription
complex (Kurooka and Honjo, 2000) and a major acetyltransferase of PGC1-α to
repress its transcriptional activity (Coste et al., 2008). Contradictory to our finding,
Hes1 has been shown to positively regulate expression of Prdm16 during mouse
neurogenesis (Kinameri et al., 2008). As Hes1 is a canonical transcriptional
repressor, it probably acts through other mediator(s) to upregulate Prdm16 indirectly
in the neural system. These observations underscore the significance of cell contextdependent action of Notch signaling (Schwanbeck et al., 2011).

I found that HFD increased Notch activity in WAT, and aNotch1 mutants are
resistant to HFD-induced obesity. These results indicate that activation of Notch
signaling is linked to the initiation and development of obesity. Our observation is
in agreement with a recent study showing that high-fat, high-cholesterol diet
increased the expression of Dll4 (a Notch ligand) in atheroma and fat tissue in
LDLR–deficient mice (Fukuda et al., 2012). Currently it is unclear how Notch
signaling is activated at onset of obesity. In addition, a recent study shows that
excessive leptin production in diet-induced obesity mice activates Notch signaling
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in metastatic breast cancer cell (Battle et al., 2014). As I observed that inhibition of
Notch reduced expression of Lep in adipose tissues, it is possible that a positive
feedback loop between Notch signaling and excessive leptin production together
accelerates the development of obesity. Treating Lepob mice with γ-secretase
inhibitor reduced body weight and ameliorated glucose metabolism, such drastic
effect may be elicited not only by browning of white adipocyte, but also through
targeting other important metabolic organs, including liver, intestine, which directly
regulates lipid metabolism and nutrient absorption respectively (Pajvani et al., 2013;
Zecchini et al., 2005). Pharmacological approaches specifically targeting the
adipose tissue will clarify the relative contribution of adipose tissue to metabolic
improvements after Notch inhibition.

One important future question is whether Notch signaling is involved in
commitment and specification of progenitors to become beige versus classical white
adipocytes. Several lines of evidence suggest that browning is an inherent capability
restricted to certain cell population that has a standby or predisposed machinery to
respond to browning cues (Liu et al., 2013; Wang et al., 2013). As Notch signaling
is widely employed to control cell fate during development, it is important to
examine how Notch regulates the cell fate specification of embryonic beige
progenitors.
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CHAPTER 3. CONSTITUTIVE ACTIVATION OF NOTCH1 INHIBITS WHITE
ADIPOGENESIS

3.1. Abstract
White adipocytes are the primary energy storage sites. In human, defect of white
adipocyte biogenesis or lipodystrophy can cause diabetes, fatty liver disease and
cardiovascular diseases. Therefore understanding the molecular regulation of white
adipocyte differentiation is essential for therapeutic intervention of lipodystrophy
disease. Here I show that constitutive activation of Notch signaling in adipocytes
dramatically inhibits white adipogenesis, leading to severe lipodystrophy and early
onset fatty liver disease of mice. Long term scarcity and malfunction of white
adipocytes altered systematic lipid and glucose metabolism, causing severe
hyperglycemia, insulin resistance as well as cancers. Thus, the hyperactive Notch
signaling in atrophic adipoytes can be therapeutically targeted to ameliorate
lipodystrophy disease and its associated diseases.
3.2. Introduction
Our previous works focused on study of the role of Notch signaling on beige
adipocyte biogenesis (Bi et al., 2014). Using aP2-Cre mediated adipose-specific
Notch mutant mice, I delineated several important functions of Notch in beige
adipocytes homeostatsis and energy metabolism. First, beige adipocytes abundance
is elevated in the adipose-specific Notch mutant mice. Second, glucose metabolism
and insulin sensitivity are improved in Notch mutant mice. Third, the Notch1 mutant
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mice are resistant to HFD-induced obesity. Fourth, I tested the preclinical potential
of the Notch inhibition on adipose energy metabolism by treating the obese mice
(Lepob) with a pharmacological inhibitor of Notch signaling, DBZ. Strikingly, DBZ
treatment dramatically ameliorated obesity, improved glucose tolerance and insulin
sensitivity, as accompanied by elevated Ucp1 expression level in white adipose
tissue. Mechanistically, I found that inhibition of Notch upregulated two beige
adipocytes master regulators, Prdm16 and Pgc1a.

Several concerns are raised by using aP2-Cre. First aP2-Cre is activated in adipose
progenitors (Shan et al., 2013), therefore the metabolic improvements of the aP2Cre mediated Notch mutant mice could be an effect of reduced white adipocytes
differentiation. Second, the aP2-Cre mouse has recently been reported to drive weak
Cre expression in the brain and macrophages (Lee et al., 2013; Martens et al., 2010;
Mullican et al., 2013b; Urs et al., 2006), future studies using more stringent
adipocyte-restricted Cre driver mice are necessary to confirm conclusions gained
from these Notch mutant mice. As an initial attempt to address these concerns, I
generated a gain-function mouse model: Adipoq/N1ICD mice. Overexpression of
the constitutive active form of Notch1 or N1ICD is activated by a highly adipocytespecific Adiponectin-Cre (Adipoq-Cre) (Eguchi et al., 2011). Consistently,
Adipoq/N1ICD mice had defects in basal as well as cold-stimulated beige adipocyte
biogenesis (Bi et al., 2014). In addition, I observed whitening of BAT in
Adipoq/N1ICD mice, manifested by lipid deposition and emergence of white
adipocytes in the classic interscapular BAT (Bi et al., 2014). Adipoq-Cre induced
Notch activation also renders the mice glucose intolerance and insulin resistance (Bi
et al., 2014). These results support the conclusion that Notch signaling inhibits
browning of WAT and deteriorates glucose metabolism of adipose tissues.
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In the current study, I fully characterized the glucose and lipid metabolism of the
Adipoq/N1ICD

mice.

Considering

the

reduced

energy

expenditure

in

Adipoq/N1ICD mice, I predict higher white fat content in these mice, compared with
WT mice. Surprisingly, Adipoq/N1ICD mice had a dramatic reduction of white fat
content or lipodystrophy even under standard diet. In addition, Adipoq/N1ICD mice
showed early-onset fatty liver disease, hyperglycemia, hyperinsulinemia and insulin
resistance. These phenotypes are even more pronounced when Adipoq/N1ICD mice
were fed with the high-fat diet. Mechanistically, activation of Notch signaling
inhibited expression of Pparγ, a key regulator of white adipocyte differentiation.
3.3. Specific Aims and Rationale
Obese adipose tissues showed activation of Notch signaling compared with healthy
lean fat, which raised the intriguing question: what is the metabolic consequence if
Notch signaling is chronically activated in adipocytes? To answer this question, I
generated the mice with constitutive activation of Notch signaling specifically in
adipocytes, henceforth called Adipoq/N1ICD. The mice were fed with either regular
chow diet or obesogenic high fat diet. I hypothesize that chronic activation of Notch
signaling in adipocytes leads to obesity and its comorbidities. For this aim, histology
and gene expression studies are performed to evaluate function of different
metabolic organs. In addition, glucose tolerance and insulin sensitivity are measured
by glucose tolerance test and insulin tolerance test, respectively.
3.4. Materials and Methods
3.4.1. Animals
All procedures involving mice were performed in accordance with Purdue
University’s Animal Care and Use Committee. Mice used were purchased from
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Jackson lab: Adiponectin–Cre (Stock# 010803) (Eguchi et al., 2011), RosaN1ICD
(Stock# 008159) (Murtaugh et al., 2003), Rosa-Td-tomato (Stock# 007914). Mice
were in C57BL/6J or mixed background and housed in the animal facility with free
access to water and standard rodent chow food or high fat diet (TD.06414 Harlan).
Energy intake assay was calculated by measuring food consumption and data was
presented as the food weight multiple its energy content, then normalized to body
weight of mice and # of days.
3.4.2. Glucose Measurement
Five µl blood collected from tail vein was dropped onto glucose test strip (AccuCheck Active, Roche) and measured by a glucometer (Accu-Check Active, Roche).
For glucose tolerance tests, mice were given intraperitoneal (IP) injection of 100 mg
ml-1 D-glucose (2 g kg-1 body weight for standard diet fed, 1 g kg-1 for high fat diet
fed) after overnight fasting, and tail blood glucose concentrations were monitored.
For insulin tolerance test, mice were fasted for 4 hours before IP administration of
human insulin (Santa Cruz) (0.75 U kg-1 body weight) and tail blood glucose
concentrations were monitored. For both GTT and ITT, mouse was singly caged
with blinded cage number and random orders.
3.4.3. Primary Adipocyte Culture
Stromal-vascular fraction (SVF) cells were isolated from subcutaneous white
adipose tissue unless otherwise stated. Adipose tissue was minced and digested with
1.5 mg mL-1 collagenase at 37 °C for 1.5 ~ 2 hours. The digestions were stopped
with DMEM containing 10% FBS, filtered through 100 µm filters and centrifuged
at 450 × g for 5 minutes. SVF cells were seeded and cultured in growth medium
containing DMEM, 20% FBS, 1% penicillin/streptomycin at 37 °C with 5 % CO2
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for 3 days. Preadipocytes were induced to differentiate with induction medium
contains DMEM, 10% FBS, 2.85 µM insulin, 0.3 µM dexamethasone (DEXA)
(Sigma) and 0.63 mM 3-isobutyl-methylxanthine (IBMX) (Cayman Chemical) for
4 days, then 4 days in differentiation medium contains DMEM, 200 nM insulin and
10 nM T3 until adipocytes mature.
3.4.4. Total RNA Extraction, cDNA Synthesis and Real-time PCR
Total RNA was extracted from cells or tissues using Trizol Reagent according to the
manufacturer’s instructions. RNA was treated with RNase-free DNase l to remove
contaminating genomic DNA. The purity and concentration of total RNA were
determined by a spectrophotometer (Nanodrop 2000c, Thermo Fisher) at 260 nm
and 280 nm. Ratios of absorption (260/280 nm) of all samples were between 1.8
and 2.0. Then 5 μg of total RNA were reverse transcribed using random primers
with M-MLV reverse transcriptase (Invitrogen). Real-time PCR was carried out in
a Roche Light Cycler 480 PCR System with SYBR Green Master Mix (Roche) and
gene-specific primers listed in Table 2.1. The 2-∆∆Ct method was used to analyze the
relative changes in each gene’s expression normalized against 18S rRNA expression.
3.4.5. Protein Extraction and Western Blot Analysis
Protein was isolated from cells or tissue using RIPA buffer contains 50 mM TrisHCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS.
Protein concentrations were determined using Pierce BCA Protein Assay Reagent
(Pierce Biotechnology). Proteins were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a polyvinylidene
fluoride (PVDF) membrane (Millipore Corporation), blocking in 5% fat-free milk
for 1 hour at room temperature, then incubated with primary antibodies in 5% milk
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overnight at 4 °C. The GAPDH (sc-32233) was from Santa Cruz Biotechnology.
The horseradish peroxidase (HRP) conjugated secondary antibody (anti-rabbit IgG
or anti-mouse IgG, Santa Cruz Biotechnology) was diluted at 1:5,000.
Immunodetection was performed using enhanced chemiluminescence western
blotting substrate (Pierce Biotechnology) and detected with a Gel Logic 2200
imaging system (Carestream). Alternatively, membrane was incubated with infrared
secondary antibody (Alexa Fluor 790 goat anti-mouse IgG, A11357, Alexa Fluor
680 goat anti-rabbit IgG, A21109, life technologies, USA) and the signals were
detected by using the Odyssey infrared image scanning system. Results shown in
figures are representative result from at least three independent experiments.
3.4.6. Hematoxylin-Eosin (H&E) and Immunohistochemistry (IHC) Staining
Adipose tissues were fixed in 10% formalin for 24 hours at room temperature. Then
the tissues were embedded into paraffin and cut at 4 µm thick, de-paraffinized, and
rehydrated through xylene, ethanol, and water by standard methods. For antigen
retrieval, slides were submerged in 0.01 M sodium citrate (pH 6.0) and heated to
96 °C for 20 minutes in a laboratory microwave (PELCO). Immunohistochemistry
was performed on a Dako Autostainer (Dako, Carpinteria, CA). Slides were
incubated with 3% hydrogen peroxide and 2.5% normal horse serum (S-2012,
Vector), followed by incubation with rabbit polyclonal anti-UCP1 primary antibody
diluted 1:200 in 2.5% normal horse serum (Vector, S-2012) for 60 minutes. Signal
was detected with an anti-rabbit IgG Polymer Detection Kit (MP-7401, Vector)
Labeling and was visualized with 3, 3’-diaminobenzidine (DAB) as the chromogen
(SK-4105, Vector). Slides were counterstained with Harris hematoxylin (EK
Industries, Joliet, IL) and whole slide digital images were collected at 20X
magnification with an Aperio Scan Scope slide scanner (Aperio, Vista, CA). Images
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shown were representative result of at least three biological replicates. Scanned
images of H&E staining were analyzed by Photoshop CS3 to calculate cell numbers.
Averaged adipocyte size was calculated as the image area divided by cell numbers.
3.4.7. Blood Insulin Measurement
5 µl blood was drawn from tails of mice and insulin was measured by a mouse
insulin ELISA kit with mouse insulin standard (Catalog # 90080, Crystal Chem,
Downers Grove, IL).
3.4.8. Statistical Analyses
Trial experiments or experiments done previously were used to determine sample
size with adequate statistical power. Measurement values that are beyond fence as
determined by interquartile range were considered as outlier and excluded from
following statistical analysis. All analyses were conducted with student t test with
two-tail distribution. Comparison with a P value < 0.05 was considered significant.
3.5. Results
3.5.1. Characterization of the Adiponectin-Cre Expression Pattern
To validate the temporal-spatial activation pattern of Cre recombinase driven by
Adiponectin promoter, Adipoq-Cre mice were bred the mice with red fluorescent
protein (RFP) reporter mice, and the progeny were named as Adipoq/Tdtomato mice.
Indeed, examination of RFP signal in different organs confirmed that RFP is only
expressed by adipocytes, while not expressed by all other metabolic organs
including heart, pancreas, liver, spleen, kidney et al (Figure 3.1). Then I cultured
preadipocytes of the mice, and induced adipogenic differentiation after the
preadipocytes reached 90% confluency. During the differentiation, RFP signal were
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checked daily. RFP signal was not detected in preadipocytes. Interestingly one day
after adipocyte differentiation, RFP positive cells were observed, which indicates
the high-sensitivity of Adiponectin promoter. The ratio of RFP+ adipocytes
gradually increased and reached nearly 100% after 1-week of differentiation
(Figure 3.1).
3.5.2. Notch Signaling Dynamics during White Adipocyte Differentiation
To understand the dynamics of Notch activity during adipocytes differentiation, I
cultured white preadipocytes isolated from epididymal adipose tissues of CpGFP
mouse, which is a GFP reporter of Notch signaling (Mizutani et al., 2007). Before
white preadipocytes reaching in the culture, GFP signal is not detectable in these
cells. This observation can be explained by two reasons. First Notch signaling is not
active in preadipocytes. Second, activation of Notch signaling requires binding of
ligand with Notch receptor, which is rare event in the low density of the cultured
cells. Upon 90% confluency of preadipocytes, I started to induce adipogenic
differentiation. Interestingly, one day after differentiation, GFP signal was detected
in a small number of cells, and the ratio of GFP+ white adipocytes gradually
increased thereafter and peaked to 75% at day 3, while decreased afterwards to 40%,
26% and 18% at day 5, day 7 and day 12 of differentiation respectively (Figure 3.2).

Consistent with our previous finding that Notch signaling inhibits beige adipocytes
biogenesis, GFP levels (Notch activity) are higher in epididymal WAT (contains
only white adipocytes) than in inguinal WAT (contains mixed white and beige
adipcoytes) and BAT (Figure 3.3). In summary, Notch signaling is more active in
white adipocytes than in beige adipocytes. In addition, Notch signaling was active
at early stage of white adipocytes differentiation, and down-regulated upon
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maturation of adipocytes. These results indicate Notch signaling regulates early
stage white adipogenesis.
3.5.3. Glucose and Lipid Metabolism of Adipoq/N1ICD Mice
Previously I found that Notch signaling inhibits beige adipocyte biogenesis, thus
reducing energy expenditure (Bi et al., 2014). Therefore I expect that
Adipoq/N1ICD mice should have more lipid storage in white adipocytes, thus
obesity, compared with WT mice. By contrary, both the size and weight of WAT in
Adipoq/N1ICD mice were significantly reduced (Figure 3.4A), a sign of
lipodystrophy. By contrast, weights of BAT, liver, spleen and several other internal
organs were increased (Figure 3.4A). Of note, histological study revealed a greatly
increased fat content in the liver of Adipoq/N1ICD mice (Figure 3.4B), a sign of
the severe hepatic steatosis (fatty liver disease). These results indicate that the
lipodystrophy is associated with an event of lipid-redistribution into other metabolic
organs, including brown fat and liver.

To evaluate the influence of adipocyte-specific Notch activation on systemic
glucose metabolism, I measured blood glucose levels of the mice under different
metabolic conditions. Intriguingly, Adipoq/N1ICD mice showed significantly
higher fed, fasted, refed and ad libido blood glucose levels, while WT mice
maintained glucose levels in a relatively normal range (Figure 3.5A). Importantly,
the severe hyperglycemia phenotype is not caused by any food intake difference
(Figure 3.5B). Consistently, in the glucose tolerance test (GTT), blood glucose
levels of Adipoq/N1ICD mice are also significantly higher, indicating glucose
intolerance (Figure 3.5C). I then measured insulin sensitivity by insulin tolerance
test (ITT). Strikingly, administration of insulin failed to reduce blood glucose of
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Adipoq/N1ICD mice, though it reduced those of WT mice (Figure 3.5D). In
addition, Adipoq/N1ICD mice showed a 15-40 fold increase of blood insulin levels
under different metabolic conditions, compared with those of WT mice (Figure
3.5E,F). These results indicate that Adipoq/N1ICD mice had severe glucose
intolerance and insulin resistance, which cause compensatory secretion of insulin
from β cells, thus leading to hyperinsulinemia in Adipoq/N1ICD mice.

Then I treated the mice with HFD, which efficiently stimulates white adipocyte
differentiation and maturation. Strikingly, N1ICD protected mice from HFDinduced obesity (Figure 3.6A–C). Similar with the mice fed on standard diet, HFD
fed Adipoq/N1ICD mice showed no response to injected insulin (Figure 3.6D).
Strikingly, the liver weight of N1ICD mice was two-times of those from WT mice,
and the ratio of liver to body weight was even tripled, compared with WT mice (Fig
3.6B,C). The extra liver weight is explained by excessive lipid accumulation, which
is revealed by H&E staining (Figure 3.6E). Accordingly, lipogenic genes were
significantly upregulated in the liver (Figure 3.6F). As liver is the main target of
insulin action, the severe fatty liver could at least partially explain the insulin
insensitivity of Adipoq/N1ICD mice. Moreover, insulin insensitivity could also be
explained by dramatically reduced adiponectin expression in WAT, which serves as
a physiological insulin sensitizer in other peripheral tissues (Figure 3.7). In
summary, HFD-fed Adipoq/N1ICD mice showed dramatic energy redistribution to
hepatocytes, thereafter caused formation of severe fatty liver and insulin resistance.
3.5.4. N1ICD Inhibits White Adipocyte Specific Gene Expression in Vivo
At molecular level, I found both beige and white adipocytes specific genes were
significantly reduced in white adipose tissues of Adipoq/N1ICD mice (Figure 3.7).
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Previous study showed that in pancreatic tumor cells, Notch target gene Hes1
suppresses expression of Pparγ (Herzig et al., 2003; Maniati et al., 2011), a
transcriptional factor that is essential for gene expression program of both beige and
white adipocytes. I therefore examined Pparγ mRNA level in adipose tissue of
Adipoq/N1ICD mice. Indeed, Pparγ mRNA level was significantly reduced in WAT
of Adipoq/N1ICD mice (Figure 3.7).
3.5.5. Aged Adipoq/N1ICD mice develop liver cancer
Importantly, Adipoq/N1ICD mice developed advanced liver cancer, which started
as early as from 9-month age (Figure 3.8A). H&E staining revealed the dramatic
lipid deposition, structural disorganization and hepatocyte hyperplasia from liver
sections of Adipoq/N1ICD mice (Figure 3.8C). Consistently, immunohistostaining
of the liver sections with Ki67, a cell proliferation marker, showed that around 20%
of the cells from Adipoq/N1ICD liver are Ki67+, while less than 2% of the cells
from wild-type liver are Ki67+ (Figure 3.9). In addition, a portion of the
Adipoq/N1ICD mice also developed lung tumor (Figure 3.9).
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Figure 3.1 Characterization of Adiponectin-Cre

First row are the images of adipose tissues. All the other rows are images of
cultured adipocytes after indicated days of differentiation.
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Figure 3.2 Result of cultured CpGFP adipocytes

(A) Image of GFP signal (black and white) in cultured CpGFP adipocytes
from different depots at different days after differnetiation. IM, induction
medium, DM, differentiation medium. Epi, Epididymal WAT, Ing, Inguinal
WAT, BAT, brown adipose tissue.
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Figure 3.3 Western blot result of adipose tissues of CpGFP mice
GFP expression in different adipose tissues from CpGFP mice
under regular room temperature (RT) or 1 week cold treatment
(cold) were analyzed by Western blot.
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Figure 3.4 Lipodystrophy and fatty liver disease of Adipoq/N1ICD mice
on standard diet

(A) Organ weights (n = 5). (B) Representative H&E staining images of
liver. *P < 0.05, **P < 0.01. Data are means ± SEM.
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Figure 3.5 Hypoglycemia, insulin resistance and hyperinsulinemia of
Adipoq/N1ICD mice

(A) Blood glucose levels at different conditions and times indicated. (B) Energy
intake assay, normalized to body weight. (C,D) Blood glucose measurement
during GTT (C) and ITT (D). (E,F) Insulin concentration of fasted and refed
mice. N = 5. #,*P < 0.05, ##, **P < 0.01, ###,***P < 0.001. *, comparison
between genotypes, #, comparison of same genotype but between time 0 and
other times. Data are means ±SEM.
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Figure 3.6 Lipodystrophy, insulin resistance and fatty liver disease of
Adipoq/N1ICD mice fed with HFD

(A) Growth curve of mice fed on high fat diet (HFD). (B,C) Organ weight(B)
and its ratio to body weight(C). (D) Blood glucose concentrations during IPITT (n = 4) performed on 5–8 month-old WT and Adipoq/N1ICD mice. (E)
Representative H&E staining of liver section of mice after 4-month HFD. (F)
Gene expression of liver from mice as in E (n = 4). n = 5 unless otherwise
indicated. *P < 0.05 and **P < 0.01. Data are means ± SEM.
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Figure 3.7 Gene expression in WAT of Adipoq/N1ICD mice
White adipocyte specific genes: Pparγ, Leptin, Adiponectin, Perilipin. All
other genes are beige adipocye specific genes. n = 4–8. *P < 0.05 and **P <
0.01. Data are means ± SEM.
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Figure 3.8 Liver cancer of 9-month old Adipoq/N1ICD mice
(A) Image of abdominal cavity. Arrow points to liver tumor. (B) Image of
liver from WT (left) and Adipoq/N1ICD (right) mice. (C) H&E staining
result of slides cut from indicated area of liver.
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Figure 3.9 Ki67 immunohistostaining of liver
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Figure 3.10 Lung cancer of 9-month old Adipoq/N1ICD mice
(A) Image of lung. (B) H&E staining result of slides cut from indicated area
of lung tumor from Adipoq/N1ICD mouse. (C) Ki67 staining of slide as in
panel B.
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Figure 3.11 Dosage effect of Notch signaling on adipocyte fate
choice and metabolism
Line sickness signifies intensity of the biological effect.
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3.6. Discussion
Interestinly, both knockout and activation of Notch1 lead to leaner phenotypes, or
reduced white adiposity of mice, though through distinct mechanisms. In adiposeNotch1 mutants (aNotch1), the leaner phenotype is attributed to the boosted beige
adipocyte abundance and function, which dissipates chemical energy stored by
white adipocytes. However, in adipocyte-specific Notch1 activation mice
(Adipoq/N1ICD), the leaner phenotype is instead caused by the dramatic inhibitory
effect of constitutive active Notch signaling on white adipocyte differentiation.
Although Adipoq/N1ICD mice showed reduced beige adipocyte abundance as well,
its metabolic consequence is overwhelmed by the concomitant defect of white
adipogenesis, which is the main source of adiposity. Besides, several other factors
should be accounted for thorough understanding of the controversy between these
models.

First, one important difference between the Notch loss- and gain-function mouse
models is that they are mediated by different Cre mouse lines. Specifically, the
Notch mutant mice models are mediated by aP2-Cre, whereas the Notch activation
model is mediated by Adipoq-Cre, which is a newer and more adipocyte-specific
(cleaner) Cre line compared with aP2-Cre line. Recent lineage tracing studies by
different groups revealed the leaky activity of aP2-Cre in other metabolic organs
(Martens et al., 2010; Mullican et al., 2013b; Urs et al., 2006). Although only small
number of cells were affected in non-adipose organs, different phenotypes were
observed when transgene was mediated by aP2-Cre, compared with that through
Adipoq-Cre. For instance, I found that the mice with aP2-Cre mediated
overexpression of N1ICD were embryonically lethal, while Adipoq/N1ICD mice
developed normally. The discrepencies were also observed in several other
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conditional transgenic studies utilizing these two Cre lines (Mullican et al., 2013b).
Similarly, it’s possible that the metabolic improvement of aNotch1 mice was
potentiated by deletion of Notch1 in the other non-adipose cell types. To test this
possibility, one future direction is to investigate whether Adipoq/Notch1 (AdipoqCre/Notch1flox/flox) mice share similar phenotypes with aNotch1 mice.

Preliminary analysis of Adipoq/Notch1 mice revealed the significantly increased
Ucp1 expression in white adipose tissues, or browning phenotype, though the
Adipoq/Notch1 mice had similar fat content compared with wild-type mice fed with
chow diet. In the future, the Adipoq/Notch1 mice will be challenged with high fat
diet to examine whether the browning Adipoq/Notch1 mice could also protect the
mice from diet-induced obesity and glucose-intolerance.

Second, the other fundamental difference between aNotch1 (knockout) and
Adipoq/N1ICD (overexpression) mice is that Notch signaling was manipulated at
different levels. Employing the Notch reporter mice, I showed that Notch signaling
was moderately active only at early stage of white adipocyte differentiation, while
was not detectable from mature adipocytes. Therefore, comparing with wild-type
adipocytes, aNotch1 adipocytes only experienced impaired Notch signaling in that
narrow window of time. However, in the Adipoq/N1ICD adipocytes, Notch
signaling was constitutively overexpressed during all stages of adipogenesis, with
Rosa-promoter driven overexpression of N1ICD at much higher level than the
endogenous level of Notch1 in wild-type cells. Therefore, the severe defect of white
adipogenesis in Adipoq/N1ICD mice could be caused by the non-physiological
effect of Notch activation. Consistently, chemical and genetic inhibition of Notch
signaling in cultured white preadipocytes had no obvious effect on the
differentiation, despite the significantly elevated expression of Pparγ. In summary,
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the physiological level of Notch signaling in wild-type white adipocytes was
deployed to safeguard the white adipocyte identity by selectively inhibiting a fate
of beige adipocyte, while had minor effect on white adipocyte differentiation
(Figure 3.11).

Despite the non-physiological aspect of Adipoq/N1ICD mouse model, it represents
an ideal lipodystrophy model to study the impact of lipid metabolism on health and
function of other non-adipose metabolic organs. Human lipodystrophy is a rare
disease condition, which can be either genetic (congenital) or acquired (Garg, 2011).
The congenital human lipodystrophy is usually caused by mutation of genes that are
involved in lipid metabolism. Based on the severity, human lipodystrophy can be
divided into two categories: generalized lipodystrophy and partial lipodystrophy.
Importantly, the metabolic consequences of lipodystrophy (too little fat) are
remarkably similar with those of obesity (too much fat), which include diabetes,
hepatic steatosis and hypertriglyceridemia.

Genetically engineered mouse models represent useful and tractable tools to study
human lipodystrophy (Savage, 2009). Strategy and features of previously reported
lipodystrophy mouse models are summarized in Table 3.1. In general, these
lipodystrophy models are generated by manipulating expression of genes that are
involved in adipogenesis or apopotic pathways. One major concern is that none of
them is stringently adipocyte-specific, making them less suitable for study of
crosstalk between fat tissue and other metabolic organs. Furthermore, most of the
previously reported lipodystrophy models had concomitant defects in brown
adipose tissues, which only exist in scarcity in adult human. Therefore, the
secondary effect elicited by the potential defects of brown fat also limited the
extrapolation of the knowledges gain from these models to human diseases. By
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contrary, Adipoq/N1ICD mice showed normal development, gene expression and
function of brown fat, making them more suitable for lipodystrophy related studies.
Table 3.1 Lipodystrophy mouse models

Model

Global

aP2 Driven

Normal
BAT

Lethality

C/EBPα

Yes

No

Yes

Neonatal

Agpat2

Yes

No

–

3 weeks

aP2-DT-A

No

Yes

No

Dosage
effect

AZIP

No

Yes

No

–

aP2-SREBP1c

No

Yes

No

–

Reference
(Wang et
al., 1995)
(Cortes et
al., 2009)
(Ross et
al., 1993)
(Moitra et
al., 1998)
(Shimomu
ra et al.,
1998)

Comparing with all other lipodystrophy models, one unique feature of the
Adipoq/N1ICD mice is that they developed late-onset hepatocellular carcinoma
(HCC). In human, long-term fatty liver disease could lead to hepatic cirrhosis, which
is strongly associated with HCC (Baffy et al., 2012). While it’s widely accepted that
the hepatic steatosis associated HCC is also linked to obesity, whether the
lipodystrophy is also a risk factor of HCC was totally unknown. My study using the
ideal lipodystrophy mouse model clearly demonstrated that HCC is also a metabolic
consequence of long-term lipodystrophy disease.
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CHAPTER 4. CONCLUDING REMARKS AND FUTURE WORKS

This study revealed important functions of Notch signaling in regulating adipocyte
homeostasis, which has significant implications in regulation of the systematic
glucose and lipid metabolism. To be specific, genetic and chemical inhibition of
Notch signaling elevated beige adipocyte abundance, which was associated with
improved glucose tolerance and insulin sensitivity. By contrary, activation of Notch
signaling both in vitro and in in vivo inhibited beige adipocyte biogenesis.

Mechanistically, canonical Notch target gene Hes1 directly inhibits expression of
Prdm16 and Pgc1a, two gatekeepers of beige adipocyte identity (Figure 4.1).
Surprisingly, constitutive activation of Notch signaling also inhibited white
adipocyte differentiation, possibly through targeting Pparγ, which led to white fat
deficiency, or lipodystrophy (Figure 4.1). Consistently, previous study showed that
Hes1 inhibited expression of Pparγ as well as C/EBPα in pancreatic cancer cells
(Figure 4.1) (Maniati et al., 2011). Of note, the Pparγ-C/EBPα complex is essential
for activation of white adipocyte specific gene expression program. Considering
both genetic and chemical inhibition of Notch signaling didn’t prompt white
adipogensis, the lipodystrophy phenotype is likely an artificial effect of the nonphysiological and chronic Notch activation.
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One important question is whether the lipodystrophy in Adipoq/N1ICD mice is the
direct cause of the metabolic syndromes. To test this possibility, adipocytes isolated
from wild-type and Adipoq/N1ICD mice will be reciprocally transplanted to
examine whether the wild-type preadipocytes could ameliorate or even rescue the
phenotypes of Adipoq/N1ICD mice. The comorbidities of lipodystrophy of
Adipoq/N1ICD mice are possibly long-term effect of lipodystrophy, thus
experiment with repetitive transplantations may be required for any obvious effect.

Activation of Notch signaling in cultured adipocytes inhibited expression of Pparγ.
Consistently, N1ICD also inhibits Pparγ expression in white adipose tissues of
Adipoq/N1ICD mice. However the N1ICD-Pparγ regulatory axis only partially
explained the phenotypes of Adipoq/N1ICD mice, which are in a larger magnitude
and a broader range compared with those of adipose-specific Pparγ knockout mice.
To comprehensively understand the molecular mechanism, microarray using
Adipoq/N1ICD adipose samples will be performed to identify novel molecular
targets of N1ICD in white adipose tissues. Knowledge gained from these studies
will open new avenues for intervention of human lipodystrophy and its deadly
comorbidities.
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Figure 4.1 Notch signaling regulates adipocyte thermogenesis

Stimulated by cold, sympathetic nervous system releases catecholamine,
which binds with β-adrenergic receptor and activates lipolysis through the
cAMP pathway. Fatty acids (FA) directly activates UCP1 for heat
production. Notch target gene Hes1 directly binds to the promoter regions of
Prdm16 and Ppargc1a (encodes PGC1α), Pparγ and C/EBPα, and inhibit
their transcription. Pparγ can complex with PGC1α and Prdm16 to activate
beige adipocyte gene program. In addition, Pparγ can also complex with
C/EBPα to activate white adipocyte genes. By interaction with NF-κB,
Notch signaling activates expression of proinflammatory cytokines, which
attracts macrophages and together cause low-grade systemic inflammation
and exacerbate insulin resistance. In obesity mellitus, infiltrated
macrophages activate transcription of Notch ligand Dll4 through NF-κB.
Dotted line indicates indirect effect.
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